Sickle Cell Disease

Mendelian MONDO:0011382 Pathograph 36 Show in embeddings browser Hematological Disease Genetic Disease

Sickle cell disease is caused by a glutamate-to-valine substitution at position 6 of beta-globin (HBB), producing hemoglobin S. On deoxygenation, hemoglobin S polymerizes into rigid fibers that deform red cells into the sickle shape, shortening their lifespan and causing chronic hemolytic anemia. Sickled cells adhere to endothelium and occlude the microcirculation, producing painful vaso-occlusive crises, nitric-oxide-depleting hemolysis, and progressive multiorgan damage.

Ask OpenScientist

Ask a research question about Sickle Cell Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
5
Pathophys.
21
Phenotypes
1
Hypotheses
36
Pathograph
3
Genes
9
Medical Actions
4
Datasets
2
Models
12
References
2
Deep Research
1
Hyp. Reports
🏷

Classifications

Harrison's Part
ONCOLOGY HEMATOLOGY GENETICS ENVIRONMENT DISEASE
🔗

Mappings

MONDO
MONDO:0011382 sickle cell disease
skos:exactMatch ORPHA:232 ORPHA:232: CONSISTENT
Orphanet's cross-reference table lists "MONDO:0011382 | Exact" for the ORPHA:232 sickle cell anemia structured record.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Orphanet records sickle cell anemia as autosomal recessive, consistent with disease from biallelic pathogenic HBB alleles.
Autosomal recessive inheritance
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"- Autosomal recessive"
Orphanet directly records autosomal recessive inheritance.
◈

Mechanistic Hypotheses

1
Canonical HbS Polymerization and Vaso-Occlusion Model
canonical_hbs_polymerization_vasoocclusion_model CANONICAL
Evidence balance 1 support
Biallelic HBB pathogenic variants (most commonly βS/βS) produce hemoglobin S, which polymerizes upon deoxygenation into rigid intracellular fibers that deform erythrocytes into the characteristic sickle shape. Sickle erythrocytes show reduced deformability, increased adhesion to endothelium and leukocytes, and shortened survival, producing chronic hemolytic anemia and recurrent vaso-occlusive episodes. Downstream consequences include painful crises, acute chest syndrome, stroke, splenic infarction, end-organ damage (kidney, lung, retina, bone), and chronic inflammation driven by free heme and reactive oxygen species.
Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Sickle_Cell_Disease/canonical_hbs_polymerization_vasoocclusion_model) found the model strongly supported with mandatory qualifications. Most decisive evidence: CRISPR-Cas9 gene therapy (exa-cel) achieves 97% freedom from severe VOCs by reactivating HbF to inhibit HbS polymerization — definitive that polymerization is the rate-limiting upstream event. Biophysical foundations (double-nucleation kinetics, extreme HbS-concentration dependence of polymerization delay) are among the most rigorously characterized in molecular medicine. Three qualifications: (1) vaso-occlusion is multicellular (endothelium, neutrophil, platelet, RBC adhesion), not purely RBC; (2) chronic hemolysis-driven oxidative stress and NO depletion drive pulmonary/renal end-organ damage independent of acute occlusion; (3) chronic inflammation persists post-HbF-reactivation, partly self-sustaining.
Deep research
OpenScientist citations 38 citations 2026-05-23T15:45:45.618885
Show evidence (1 reference)
PMID:29614632 SUPPORT Other
"Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
Canonical mechanism review used as the seed reference for the hypothesis-search deep-research run.
⚙

Pathophysiology

5
Hemoglobin Polymerization
Deoxygenated HbS polymerizes into rigid fibers, deforming red blood cells into sickle shape. HbS has glutamic acid to valine substitution at position 6 of beta-globin.
protein polymerization GO:0051258 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves protein polymerization (GO:0051258). GO:0051258 is a biological process from the Gene Ontology. response to hypoxia GO:0001666 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves response to hypoxia (GO:0001666). GO:0001666 is a biological process from the Gene Ontology.
Computational models
Lu stochastic kinetic model of HbS polymerization and erythrocyte sickling KINETIC Simulates oxygen-dependent HbS nucleation and fiber growth using classical nucleation theory and chemical rate laws.
Downstream
Red Blood Cell Sickling HbS polymer formation deforms erythrocytes and drives sickling.
Show evidence (2 references)
PMID:29614632 SUPPORT Other
"Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
HbS polymerization is concentration-dependent and leads to sickling.
PMID:3965046 SUPPORT
"Our results support the hypothesis that the intracellular polymerization of HbS is the primary determinant of the severity of both anemia and clinical symptomatology in the sickle hemoglobinopathies."
Establishes HbS polymerization as the primary determinant of clinical severity in sickling syndromes.
Red Blood Cell Sickling
Sickled RBCs are rigid and fragile, leading to hemolytic anemia and shortened RBC lifespan (10-20 days vs normal 120 days).
Red Blood Cell CL:0000232 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Red Blood Cell, annotated with erythrocyte (CL:0000232). CL:0000232 is a cell type from the Cell Ontology.
erythrocyte homeostasis GO:0034101 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves erythrocyte homeostasis (GO:0034101). GO:0034101 is a biological process from the Gene Ontology. positive regulation of erythrocyte clearance GO:0034108 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves positive regulation of erythrocyte clearance (GO:0034108). GO:0034108 is a biological process from the Gene Ontology.
Computational models
Zheng multiscale QSP model of autologous gene therapy KINETIC Simulates replacement of HbS-containing cells by longer-lived transduced cells expressing an anti-sickling hemoglobin after autologous gene therapy.
Lu stochastic kinetic model of HbS polymerization and erythrocyte sickling KINETIC Converts simulated intracellular fiber-bundle growth into sickling time and the predicted fraction of sickled erythrocytes.
Downstream
Vaso-Occlusion Rigid sickled erythrocytes increase microvascular obstruction and endothelial interactions.
Chronic Hemolysis Repeated membrane injury promotes erythrocyte destruction and clearance.
Show evidence (1 reference)
PMID:29614632 SUPPORT Other
"In double heterozygosis for Hb S and C (SC disease) dehydration is the determining factor in disease pathophysiology."
Cell dehydration promotes sickling and fragility of red blood cells.
Vaso-Occlusion
Sickled cells adhere to vascular endothelium and obstruct microcirculation, causing tissue ischemia and pain crises. Inflammation amplifies adhesion.
Endothelial Cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Endothelial Cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology.
leukocyte adhesion to vascular endothelial cell GO:0061756 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves leukocyte adhesion to vascular endothelial cell (GO:0061756). GO:0061756 is a biological process from the Gene Ontology. positive regulation of cell adhesion GO:0045785 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves positive regulation of cell adhesion (GO:0045785). GO:0045785 is a biological process from the Gene Ontology.
Downstream
Pain Crises Microvascular obstruction causes ischemic vaso-occlusive pain episodes.
Chronic Organ Damage Recurrent vaso-occlusion causes ischemia-reperfusion injury in end organs.
Acute Chest Syndrome
Chest Pain
Stroke
Priapism
Leg Ulcers
Avascular Necrosis
Osteomyelitis
Finger Dactylitis
Show evidence (1 reference)
PMID:24277079 SUPPORT Model Organism
"intravascular hemolysis in SCD releases heme that activates endothelial TLR4 signaling leading to WPB degranulation, NF-κB activation, and vaso-occlusion."
Heme released from hemolysis triggers TLR4 signaling on endothelial cells, leading to Weibel-Palade body degranulation and release of P-selectin and von Willebrand factor, which promote adhesion and vaso-occlusion.
Chronic Hemolysis
Intravascular hemolysis releases free hemoglobin, scavenging nitric oxide and causing endothelial dysfunction, pulmonary hypertension, and stroke risk.
nitric oxide metabolic process GO:0046209 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves nitric oxide metabolic process (GO:0046209). GO:0046209 is a biological process from the Gene Ontology. response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology.
Computational models
Zheng multiscale QSP model of autologous gene therapy KINETIC Reproduces the shortened red-cell lifespan and compensatory erythropoietic state used to distinguish the SCD and healthy steady states.
Downstream
Chronic Organ Damage Nitric oxide depletion and oxidative stress drive progressive endothelial and tissue injury.
Chronic Hemolytic Anemia Sustained erythrocyte destruction contributes to chronic hemolytic anemia.
Jaundice
Pigment Gallstones
Reticulocytosis
Pulmonary Arterial Hypertension
Show evidence (2 references)
PMID:15998894 SUPPORT
"hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."
Hemolysis releases both arginase (which depletes L-arginine, the substrate for nitric oxide synthesis) and free hemoglobin (which directly scavenges nitric oxide), leading to endothelial dysfunction and pulmonary hypertension.
PMID:15998894 SUPPORT
"The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease."
Low arginine bioavailability due to increased arginase activity is directly associated with pulmonary hypertension severity and mortality risk in SCD patients.
Chronic Organ Damage
Repeated vaso-occlusion and ischemia-reperfusion injury cause progressive damage to spleen, kidneys, lungs, and brain.
response to ischemia GO:0002931 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves response to ischemia (GO:0002931). GO:0002931 is a biological process from the Gene Ontology. cellular response to oxidative stress GO:0034599 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves cellular response to oxidative stress (GO:0034599). GO:0034599 is a biological process from the Gene Ontology.
Downstream
Splenic Sequestration
Abnormality of the Spleen
Recurrent Infections
Thrombocytosis
Chronic Kidney Disease
Retinopathy
Pulmonary Arterial Hypertension
Osteoporosis
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Sickle Cell Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Blood 2
Thrombocytosis FREQUENT HP:0001894 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thrombocytosis (HP:0001894). HP:0001894 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0001894 | Thrombocytosis | Frequent (79-30%)"
Orphanet records thrombocytosis as a frequent phenotype.
Reticulocytosis FREQUENT HP:0001923 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reticulocytosis (HP:0001923). HP:0001923 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0001923 | Reticulocytosis | Frequent (79-30%)"
Orphanet records reticulocytosis as a frequent phenotype.
Cardiovascular 3
Splenic Sequestration OCCASIONAL Splenomegaly HP:0001744 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Splenomegaly (HP:0001744). HP:0001744 is a phenotype from the Human Phenotype Ontology.
Medical emergency in children
Stroke OCCASIONAL Ischemic stroke HP:0002140 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ischemic Stroke (HP:0002140). HP:0002140 is a phenotype from the Human Phenotype Ontology.
Children and adults at risk
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0002140 | Ischemic stroke | Occasional (29-5%)"
Orphanet records ischemic stroke as an occasional phenotype.
Pulmonary Arterial Hypertension OCCASIONAL HP:0002092 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary arterial hypertension (HP:0002092). HP:0002092 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0002092 | Pulmonary arterial hypertension | Occasional (29-5%)"
Orphanet records pulmonary arterial hypertension as an occasional phenotype.
Digestive 1
Jaundice FREQUENT HP:0000952 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Jaundice (HP:0000952). HP:0000952 is a phenotype from the Human Phenotype Ontology.
From chronic hemolysis
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0000952 | Jaundice | Frequent (79-30%)"
Orphanet records jaundice as a frequent phenotype.
Eye 1
Retinopathy FREQUENT HP:0000488 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinopathy (HP:0000488). HP:0000488 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0000488 | Retinopathy | Frequent (79-30%)"
Orphanet records retinopathy as a frequent phenotype.
Genitourinary 2
Priapism OCCASIONAL HP:0200023 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Priapism (HP:0200023). HP:0200023 is a phenotype from the Human Phenotype Ontology.
In males
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0200023 | Priapism | Occasional (29-5%)"
Orphanet records priapism as an occasional phenotype.
Chronic Kidney Disease FREQUENT HP:0012622 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic kidney disease (HP:0012622). HP:0012622 is a phenotype from the Human Phenotype Ontology.
Recurrent vaso-occlusion and hemolysis contribute to sickle nephropathy.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0012622 | Chronic kidney disease | Frequent (79-30%)"
Orphanet records chronic kidney disease as a frequent phenotype.
Immune 2
Recurrent Infections VERY_FREQUENT HP:0002719 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent infections (HP:0002719). HP:0002719 is a phenotype from the Human Phenotype Ontology.
Functional asplenia and impaired splenic clearance increase infection risk.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0002719 | Recurrent infections | Very frequent (99-80%)"
Orphanet records recurrent infections as a very frequent phenotype.
Osteomyelitis FREQUENT HP:0002754 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteomyelitis (HP:0002754). HP:0002754 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0002754 | Osteomyelitis | Frequent (79-30%)"
Orphanet records osteomyelitis as a frequent phenotype.
Integument 1
Leg Ulcers OCCASIONAL Skin ulcer HP:0200042 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Skin Ulcer (HP:0200042). HP:0200042 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0200042 | Skin ulcer | Occasional (29-5%)"
Orphanet records skin ulcer as an occasional phenotype.
Musculoskeletal 1
Osteoporosis FREQUENT HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0000939 | Osteoporosis | Frequent (79-30%)"
Orphanet records osteoporosis as a frequent phenotype.
Respiratory 1
Acute Chest Syndrome OCCASIONAL Respiratory distress HP:0002098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Respiratory Distress (HP:0002098). HP:0002098 is a phenotype from the Human Phenotype Ontology.
Leading cause of death
Show evidence (2 references)
PMID:24620350 SUPPORT Model Organism
"Sickle cell disease (SCD) is characterized by recurring episodes of vascular occlusion in which neutrophil activation plays a major role. The disease is associated with chronic hemolysis with elevated cell-free hemoglobin and heme."
Neutrophil activation and hemolysis contribute to vascular occlusion and acute complications like acute chest syndrome.
PMID:24620350 SUPPORT Model Organism
"we have identified a novel role for heme in the induction of neutrophil extracellular trap (NET) formation in SCD. NETs are decondensed chromatin decorated by granular enzymes and are released by activated neutrophils."
Heme triggers neutrophil extracellular trap formation, which contributes to acute lung injury and acute chest syndrome in sickle cell disease.
Constitutional 2
Pain Crises VERY_FREQUENT HP:0012531 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pain Crisis, annotated with Pain (HP:0012531). HP:0012531 is a phenotype from the Human Phenotype Ontology.
Acute vaso-occlusive episodes
Show evidence (2 references)
PMID:24277079 SUPPORT Model Organism
"Heme rapidly (5 minutes) mobilized Weibel-Palade body (WPB) P-selectin and VWF onto EC and vessel wall surfaces and activated EC nuclear factor κB (NF-κB)."
Heme-induced rapid release of adhesion molecules (P-selectin and von Willebrand factor) triggers vaso-occlusion, which causes pain crises in sickle cell disease.
ORPHA:232 SUPPORT Other
"HP:0012531 | Pain | Very frequent (99-80%)"
Orphanet independently records pain as a very frequent HPO phenotype of sickle cell anemia.
Chest Pain FREQUENT HP:0100749 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chest pain (HP:0100749). HP:0100749 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0100749 | Chest pain | Frequent (79-30%)"
Orphanet records chest pain as a frequent phenotype.
Other 5
Chronic Hemolytic Anemia OBLIGATE HP:0004870 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic hemolytic anemia (HP:0004870). HP:0004870 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:15998894 SUPPORT
"hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase"
Chronic hemolysis is a hallmark feature of sickle cell disease.
ORPHA:232 SUPPORT Other
"HP:0004870 | Chronic hemolytic anemia | Obligate (100%)"
Orphanet records chronic hemolytic anemia as an obligate phenotype of sickle cell anemia.
Abnormality of the Spleen FREQUENT HP:0001743 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the spleen (HP:0001743). HP:0001743 is a phenotype from the Human Phenotype Ontology.
Broad Orphanet spleen phenotype complementing specific splenic sequestration risk.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0001743 | Abnormality of the spleen | Frequent (79-30%)"
Orphanet records spleen abnormality as a frequent phenotype.
Pigment Gallstones FREQUENT HP:0011981 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pigment gallstones (HP:0011981). HP:0011981 is a phenotype from the Human Phenotype Ontology.
Chronic hemolysis increases bilirubin turnover and pigment gallstone risk.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0011981 | Pigment gallstones | Frequent (79-30%)"
Orphanet records pigment gallstones as a frequent phenotype.
Avascular Necrosis FREQUENT HP:0010885 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Avascular necrosis (HP:0010885). HP:0010885 is a phenotype from the Human Phenotype Ontology.
Vaso-occlusion can compromise bone blood supply.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0010885 | Avascular necrosis | Frequent (79-30%)"
Orphanet records avascular necrosis as a frequent phenotype.
Finger Dactylitis OCCASIONAL HP:0031090 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Finger dactylitis (HP:0031090). HP:0031090 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"HP:0031090 | Finger dactylitis | Occasional (29-5%)"
Orphanet records finger dactylitis as an occasional phenotype.
🧬

Genetic Associations

3
HBB (Causative)
Gene: HBB hgnc:4827 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HBB (hgnc:4827). hgnc:4827 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:18667698 SUPPORT
"Sickle cell disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mortality."
Confirms SCD is a monogenic blood disorder caused by HBB mutations.
BCL11A (Modifier)
Gene: BCL11A hgnc:13221 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BCL11A (hgnc:13221). hgnc:13221 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:18667698 SUPPORT
"Common single nucleotide polymorphisms (SNPs) at the BCL11A and HBS1L-MYB loci have been implicated previously in HbF level variation"
BCL11A polymorphisms regulate fetal hemoglobin levels and modify sickle cell disease severity.
HBS1L-MYB (Modifier)
Show evidence (1 reference)
PMID:18667698 SUPPORT
"Together, common SNPs at the BCL11A, HBS1L-MYB, and beta-globin (HBB) loci account for >20% of the variation in HbF levels in SCD patients."
HBS1L-MYB locus polymorphisms are major modifiers of HbF levels in sickle cell disease.
🗃️

External Assertions

1
Orphanet sickle cell anemia structured record
Orphanet structured disease record ORPHA:232
Orphanet curates ORPHA:232 as the sickle cell anemia record, a severe homozygous HbS form within sickle cell disease, and provides exact cross-references to this entry's MONDO identifier plus OMIM, MeSH, MedDRA, UMLS, and other registry identifiers.
Show evidence (4 references)
ORPHA:232 SUPPORT Other
"ORPHA:232 Sickle cell anemia"
The Orphanet structured record heading identifies ORPHA:232 as the sickle cell anemia disease record.
ORPHA:232 SUPPORT Other
"MONDO:0011382 | Exact"
Orphanet maps ORPHA:232 exactly to the MONDO disease identifier used by this entry.
ORPHA:232 SUPPORT Other
"OMIM:603903 | Exact"
Orphanet lists OMIM:603903 as an exact cross-reference.
+ 1 more reference
💊

Medical Actions

9
Hydroxyurea
Increases HbF, reduces pain crises, first-line disease-modifying therapy.
Show evidence (1 reference)
PMID:7715639 SUPPORT
"the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001)"
Landmark RCT demonstrating hydroxyurea reduces painful crises by nearly half in sickle cell disease.
Voxelotor
HbS polymerization inhibitor formerly used to improve anemia; voluntarily withdrawn from worldwide markets in 2024 due to postmarketing safety concerns.
Crizanlizumab
P-selectin inhibitor for reducing vaso-occlusive crises; regulatory status is jurisdiction-dependent after EU authorization revocation was recommended in 2023 when STAND did not confirm benefit.
L-Glutamine
Reduces oxidative stress in RBCs.
Blood Transfusions
Chronic transfusions for stroke prevention, acute for severe anemia.
Pain Management
NSAIDs, opioids for acute crises.
Penicillin Prophylaxis
In children to prevent pneumococcal sepsis.
Hematopoietic Stem Cell Transplant
Curative option for selected patients.
Gene Therapy
Autologous gene therapy using multiple platforms (lentiviral, shmiR-BCL11A, CRISPR-Cas9, CRISPR-Cas12a, base-editing) for BCL11A-mediated fetal hemoglobin reactivation or altered hemoglobin synthesis. FDA-approved: exagamglogene autotemcel (exa-cel, CRISPR-Cas9) and lovotibeglogene autotemcel (lovo-cel, lentiviral). Reni-cel (CRISPR-Cas12a) and risto-cel (base editing) in advanced trials.
Show evidence (9 references)
PMID:38661449 SUPPORT Human Clinical
"Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the..."
CRISPR-Cas9 gene editing of the BCL11A enhancer reactivates fetal hemoglobin, which prevents sickling.
PMID:38661449 SUPPORT Human Clinical
"Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more."
In phase 3 clinical trials, exagamglogene autotemcel (exa-cel) eliminated vaso-occlusive crises in 97% of patients for 12+ months, demonstrating high therapeutic efficacy.
PMID:42400217 SUPPORT Human Clinical
"Autologous gene therapy has emerged as a potential curative strategy, but trial efficacy must be interpreted together with mobilization, apheresis collection, manufacturing, conditioning, cost, fertility preservation, and long-term surveillance requirements."
Systematic review confirms autologous gene therapy as emerging curative strategy while emphasizing treatment-delivery complexity and practical feasibility factors.
+ 6 more references
🌍

Environmental Factors

5
Dehydration
dehydration XCO:0001602 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is dehydration (XCO:0001602). XCO:0001602 is an exposure from the Experimental Conditions Ontology.
Triggers sickling
Show evidence (1 reference)
PMID:29614632 SUPPORT Other
"Cell dehydration is a distinguishing characteristic of sickle cell disease and an important contributor to disease pathophysiology. Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
Dehydration increases intracellular HbS concentration, promoting sickling.
Mechanism Target:
TRIGGERS Hemoglobin Polymerization — An unusually exact exposure-to-node fit, and the reason is physical: polymerisation depends steeply on intracellular haemoglobin concentration, so removing water from the cell acts on this node directly rather than through anything in between. The cited sentence says exactly that.
Show evidence (1 reference)
PMID:29614632 SUPPORT Other
"Cell dehydration is a distinguishing characteristic of sickle cell disease and an important contributor to disease pathophysiology. Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
States that because polymerisation depends uniquely on cellular haemoglobin S concentration, cell dehydration promotes polymerisation and sickling. Exposure, mechanism and node in one sentence.
Hypoxia
Promotes HbS polymerization
Show evidence (1 reference)
PMID:29614632 SUPPORT Other
"Each of these pathways exhibit unique characteristics in regulation by oxygen tension, intracellular and extracellular environment"
Low oxygen tension affects ion transport pathways that contribute to sickling.
Mechanism Target:
TRIGGERS Hemoglobin Polymerization — Direct because the node itself is about deoxygenated haemoglobin S, so falling oxygen tension acts on it with nothing in between. Graded partial rather than supporting despite that tight fit, because the available sentence is about oxygen tension regulating ion transport pathways and never states that hypoxia promotes polymerisation. The directness comes from the node's own wording, not from the evidence.
Show evidence (1 reference)
PMID:29614632 SUPPORT Other
"Each of these pathways exhibit unique characteristics in regulation by oxygen tension, intracellular and extracellular environment"
Reports that the ion transport pathways discussed are regulated by oxygen tension. It connects oxygen to the cell's water handling rather than to polymerisation at this node.
Cold Exposure
exposure to decreased temperature ECTO:0001057 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to decreased temperature (ECTO:0001057). ECTO:0001057 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Associated with vaso-occlusion. The human evidence is seasonal and correlational, with a small effect size; the causal step from cold exposure to vaso-occlusion has been shown directly only in a mouse model.
Show evidence (2 references)
PMID:34540479 SUPPORT Human Clinical
"Total episodes of VOC peaked during January (n=44), while they were lowest in July (n=16)."
Human observational evidence that vaso-occlusive crises cluster in the coldest month and are least frequent in the warmest. PARTIAL because the study's own temperature correlation is weak, at r = -0.05, and a seasonal peak does not isolate cold from the other things that vary with season.
PMID:37774369 SUPPORT Model Organism
"Cold exposure induced more vaso-occlusion in nonhyperalgesic HbSS mice (33%) than in HbAA mice (11%) or HbSS mice left at room temperature (1%)."
Establishes the causal step in a sickle mouse model, with both a genotype and a temperature control. Model-organism evidence, so it is paired with the human seasonal data rather than standing alone for a human claim.
High Altitude
Low oxygen triggers crises
Show evidence (2 references)
PMID:7340130 SUPPORT Human Clinical
"The average risk of crisis was higher for both groups while in the mountains (37.9 percent and 56.6 percent, respectively) than it was during airplane travel (10.8 percent and 13.5 percent, respectively)."
Quantifies painful-crisis risk by altitude exposure in patients with sickle cell disease, and shows it rises with the degree of hypoxaemia: mountain stays carry several times the risk of pressurised air travel.
PMID:7340130 SUPPORT Human Clinical
"Patients with sickle cell disease are at high risk of crisis in the mountains, and we advise those with intact spleens to breathe supplemental oxygen during air travel."
The study's own conclusion, stated as a clinical recommendation, that altitude exposure is a crisis risk in this disease.
Infections
Infectious agent exposure ECTO:3000000 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is Infectious agent exposure, annotated with exposure to organism (ECTO:3000000). ECTO:3000000 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Common trigger for crises
Show evidence (1 reference)
PMID:39568431 SUPPORT Human Clinical
"Patients with SCD have significant immunodeficiency and are more likely to suffer severe and life-threatening complications of infection, and additionally infections can trigger complications of SCD itself."
States the two-way relationship this entry depends on: the disease raises susceptibility to infection, and infection in turn triggers complications of the disease. The second clause is the exposure claim made here.
🔬

Biochemical Markers

6
Hemoglobin (Decreased)
Context: Chronic anemia, Hb typically 6-9 g/dL
Pathograph Readouts
Readout Of Chronic Hemolysis Negative Monitoring
Lower hemoglobin concentration reflects anemia from ongoing hemolysis and marrow compensation limits.
Hemoglobin response rate
Accelerated Or Traditional Context Dependent Surrogate Endpoint
Patients with sickle cell disease; Proxysmal nocturnal hemoglobinuria (PNH)
Hemoglobin response rate
Accelerated Reasonably Likely Surrogate Endpoint
Patients with sickle cell disease
Show evidence (2 references)
PMID:31199090 SUPPORT Human Clinical
"The primary end point was the percentage of participants who had a hemoglobin response, which was defined as an increase of more than 1.0 g per deciliter from baseline at week 24 in the intention-to-treat analysis."
This phase 3 SCD trial used hemoglobin response as a blood biomarker endpoint, supporting hemoglobin concentration as a clinically measured biomarker in SCD.
PMID:15998894 SUPPORT
"hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."
Chronic hemolysis releases free hemoglobin, contributing to anemia.
Reticulocytes (Elevated)
Context: Compensatory increased production
Pathograph Readouts
Readout Of Chronic Hemolysis Positive Monitoring
Elevated reticulocytes reflect marrow response to red-cell destruction in chronic hemolysis.
Show evidence (1 reference)
PMID:16291595 SUPPORT Human Clinical
"In a cohort of 213 patients with sickle cell disease, we found statistically significant associations of steady-state LDH with low levels of hemoglobin and haptoglobin and high levels of reticulocytes, bilirubin, plasma hemoglobin, aspartate aminotransferase, arginase, and soluble adhesion molecules."
This SCD cohort study supports elevated reticulocytes as part of the hemolysis-associated biomarker profile.
Bilirubin (Elevated)
Context: Indirect, from hemolysis
Pathograph Readouts
Readout Of Chronic Hemolysis Positive Monitoring
Higher indirect bilirubin reflects heme catabolism from accelerated red-cell breakdown.
Show evidence (1 reference)
PMID:31199090 SUPPORT Human Clinical
"At week 24, the 1500-mg voxelotor group had significantly greater reductions from baseline in the indirect bilirubin level and percentage of reticulocytes than the placebo group."
This phase 3 SCD trial used indirect bilirubin as a hemolysis biomarker that changed with treatment.
LDH (Elevated)
Context: Hemolysis marker
Pathograph Readouts
Readout Of Chronic Hemolysis Positive Prognostic
Higher LDH reflects intravascular hemolysis and has been associated with hemolysis-linked vasculopathy risk.
Show evidence (1 reference)
PMID:16291595 SUPPORT Human Clinical
"We hypothesized that serum LDH may represent a convenient biomarker of intravascular hemolysis and NO bioavailability, characterizing a clinical subphenotype of hemolysis-associated vasculopathy."
This human SCD cohort paper directly evaluates serum LDH as a biomarker of intravascular hemolysis and nitric-oxide bioavailability.
HbS (Present)
Context: Greater than 50% on hemoglobin electrophoresis
Pathograph Readouts
Correlates With Hemoglobin Polymerization Threshold Dependent Diagnostic
HbS fraction identifies the polymerizing hemoglobin substrate; risk depends on genotype, oxygenation, concentration, and modifying hemoglobins.
Show evidence (1 reference)
PMID:31199090 SUPPORT Human Clinical
"Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has potential to favorably modify disease outcomes. Voxelotor is an HbS polymerization inhibitor."
This phase 3 SCD trial frames HbS polymerization as the proximal disease biochemical process targeted by therapy.
Fetal Hemoglobin (Variable)
Context: Higher HbF modifies SCD severity and is induced by therapies such as hydroxyurea.
Pathograph Readouts
Correlates With Hemoglobin Polymerization Negative Pharmacodynamic
Higher HbF is associated with reduced HbS polymerization and can serve as a pharmacodynamic readout for HbF-inducing therapies.
Show evidence (2 references)
PMID:18667698 SUPPORT Human Clinical
"Interindividual variation in fetal hemoglobin (HbF) expression is a known and potentially heritable modifier of SCD severity. High HbF levels are correlated with reduced morbidity and mortality."
This human genetic association study supports HbF level as a clinically meaningful modifier biomarker in SCD.
PMID:7715639 SUPPORT Human Clinical
"In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity."
This sickle-cell anemia trial background supports HbF induction as a treatment-linked biomarker.
📈

Progression

1
Onset
Age: All ages
Orphanet records onset across all ages for sickle cell anemia.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"Age of onset: All ages"
Orphanet records all ages as the age-of-onset category.
📊

Prevalence

5
Global population, 2021
7.74 million people living with sickle cell disease
Global Burden of Disease 2021 estimates show substantial worldwide living prevalence, with highest burden in sub-Saharan Africa and increasing total case counts over time.
Show evidence (1 reference)
PMID:37331373 SUPPORT Human Clinical
"The number of people living with sickle cell disease globally increased by 41·4% (38·3-44·9), from 5·46 million (4·62-6·45) in 2000 to 7·74 million (6·51-9·2) in 2021."
This GBD 2021 systematic analysis provides the best current global living prevalence estimate for sickle cell disease.
Live births in 11 US Sickle Cell Data Collection states, 2016-2020
Birth Prevalence 48.3 per 100,000 1–9 per 10,000
In the same surveillance dataset, birth prevalence among non-Hispanic Black newborns was 28.54 per 10,000 live births (1 in 350), showing the marked population-specific burden of disease in the United States.
Show evidence (1 reference)
PMID:38547025 SUPPORT Human Clinical
"SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births and 28.54 per 10,000 (one in every 350) non-Hispanic Black newborns."
This multistate newborn-screening analysis provides a contemporary population-based US birth-prevalence estimate for sickle cell disease.
Europe (Orphanet point prevalence)
Point Prevalence 10.0–50.0 per 100,000 1–9 per 10,000
Orphanet classifies European point prevalence for sickle cell anemia in the 1-5 per 10,000 band.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"1-5 / 10 000 | Europe | Point prevalence | PMID:2019"
Orphanet's epidemiology table provides this European point-prevalence class.
United States (Orphanet point prevalence)
Point Prevalence 10.0–50.0 per 100,000 1–9 per 10,000
Orphanet classifies United States point prevalence for sickle cell anemia in the 1-5 per 10,000 band.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"1-5 / 10 000 | United States | Point prevalence | PMID:20331952,INST"
Orphanet's epidemiology table provides this United States point-prevalence class.
United States live births (Orphanet)
Birth Prevalence 10.0–50.0 per 100,000 1–9 per 10,000
Orphanet classifies United States birth prevalence for sickle cell anemia in the 1-5 per 10,000 live-birth band.
Show evidence (1 reference)
ORPHA:232 SUPPORT Other
"1-5 / 10 000 | United States | Prevalence at birth | PMID:17183567"
Orphanet's epidemiology table provides this United States prevalence-at-birth class.
📊

Related Datasets

4
Fetal hemoglobin in sickle cell disease patients from Tanzania ega:EGAS00001000990
Levels of fetal hemoglobin have been associated with differences in severity and outcome of sickle cell disease (SCD). While some genetic associations have been reported between SNPs and HbF level, little of the variance in the trait is explained, and most studies have focused on African American, rather than African samples. We have carried out a GWAS in a collection of SCD patients from Dar es Salaam, Tanzania. This sample represents a diverse, metropolitan collection of individuals from East Africa. Omni 2.5M genotypes and HbF levels (measured after 5 years of age) are available.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Sickle Cell Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Nontargeted plasma proteomics analysis uncovers candidate biomarkers for renal disease and pulmonary hypertension in patients with sickle cell disease massive:MSV000093893
Fifteen microliters of plasma from sickle cell disease patients, and pooled samples, were diluted with 5% deoxycholate and 10 mM DTT, followed by heating at 80 degC for 30 min, alkylation with 25 mM iodoacteamide and digestion with modified trypsin for 4 h at 37 degC. After acidification, samples were filtered.
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Sickle Cell Disease"). Retrieved 2026-08-02.
NHBLI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU) dbgap:phs001466
Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS) within circulating erythrocytes resulting in hemolytic anemia, vascular occlusion, and end organ damage due to alterations in the shape and deformability of the cell membrane. The disease is inherited in an autosomal recessive pattern, and is most commonly caused by a single nucleotide substitution in the hemoglobin subunit beta (HBB) gene located on chromosome 11.
Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Sickle Cell Disease"). Retrieved 2026-08-02.
Metabolic and Proteomic Changes in Sickle Cell Disease and thalassemia Mouse Splenic and Hepatic Macrophages and Peripheral Blood Mononuclear cells massive:MSV000092457
Sickle cell disease and Beta-thalassemia represent hemoglobinopathies arising from dysfunctional or under produced beta-globin chains, respectively. In both diseases, red blood cell injury and anemia are the impetus for end organ injury. Because persistent erythrophagocytosis is a hallmark of these genetic maladies it is critical to understand how macrophage phenotype polarizations in tissue compartments can inform on disease progression. Murine models of sickle cell disease and Beta-thalassemia allow for a basic understanding of mechanisms and provide for translation to human disease.
mouse MULTI OMICS
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Sickle Cell Disease"). Retrieved 2026-08-02.
🧮

Computational Models

2
Zheng multiscale QSP model of autologous gene therapy ODE equations and parameters in the article and supporting information KINETIC
Deterministic ordinary-differential-equation model coupling hematopoietic stem-cell engraftment, erythroid differentiation, red-cell turnover, globin assembly, and oxygen-regulated erythropoiesis. Healthy and SCD parameterizations are extended with myeloablative preconditioning and transplantation of CD34-positive cells expressing an anti-sickling gamma-globin.
PMID:34139105
Variable Model ID Unit Ontology Mappings Phenotype Thresholds
Initial transduced CD34-positive cell dose
Number of autologous progenitor cells infused after preconditioning
 initial_dose cells
Long-term hematopoietic stem-cell fraction
Fraction of the infused dose capable of stable long-term engraftment
 LT-HSC_fraction fraction
Mean vector copy number
Model proxy for the fraction of infused cells carrying the therapeutic vector
 VCN copies/cell
Preconditioning depletion
Fractional depletion of endogenous hematopoietic progenitor pools
 preconditioning fraction
Anti-sickling hemoglobin
Peripheral-blood concentration of the modeled therapeutic hemoglobin
 HbNew g/dL
Transduced red blood cells
Circulating red cells derived from transduced progenitors
 transduced_RBC cells
Pathograph links
Chronic Hemolysis partially recapitulates fidelity: moderate Reproduces the shortened red-cell lifespan and compensatory erythropoietic state used to distinguish the SCD and healthy steady states.
Limitations: Hemolysis is represented through a fixed mean red-cell lifespan rather than explicit intravascular and extravascular destruction mechanisms.
Red Blood Cell Sickling perturbs fidelity: moderate Simulates replacement of HbS-containing cells by longer-lived transduced cells expressing an anti-sickling hemoglobin after autologous gene therapy.
Limitations: The model predicts hemoglobin composition and a non-sickled-cell fraction but does not explicitly simulate HbS nucleation, fiber growth, membrane deformation, vaso-occlusion, or organ injury.
Findings
Simulated reconstitution is biphasic: short-lived progenitors generate an early wave of transduced red cells, while long-term stem-cell engraftment sustains later production.
Show evidence (1 reference)
PMID:34139105 SUPPORT Computational
"Post-treatment dynamics show an early phase of reconstitution due to short lived stem cells, followed by a sustained RBC production from stable engraftment of long-term stem cells."
Directly reports the model's two predicted reconstitution phases.
Initial transduced-cell dose and myeloablative preconditioning intensity were the strongest positive determinants of modeled long-term outcome.
Show evidence (1 reference)
PMID:34139105 SUPPORT Computational
"The initial dose of transduced stem cells, and the intensity of myeloablative bone marrow preconditioning are predicted to most positively impact long-term outcomes."
Directly states the principal long-term sensitivity result.
Curated from the publication and supporting equations; no exact deposited implementation was identified. Important assumptions include deterministic population averages, at most one vector copy per cell, fixed fractional progenitor depletion, immediate marrow homing, omission of non-erythroid hematopoiesis and iron/heme handling, and empirical oxygen feedback.
Show evidence (1 reference)
PMID:34139105 SUPPORT Computational
"We used ordinary differential equations to model RBC production from progenitor cells in the bone marrow, and hemoglobin assembly from its constituent globin monomers."
Establishes the mathematical form and the coupled erythropoiesis and hemoglobin-assembly scope of the model.
Lu stochastic kinetic model of HbS polymerization and erythrocyte sickling Stochastic kinetic equations and parameters in the article and supplementary materials KINETIC
Patient- and organ-parameterized model coupling oxygen-dependent HbS solubility, homogeneous and heterogeneous nucleation, fiber growth, and a mechanical criterion for red-cell sickling. Inputs include oxygen tension, deoxygenation time, temperature, cell volume, hemoglobin concentration, and hemoglobin composition.
PMID:31457104
Variable Model ID Unit Ontology Mappings Phenotype Thresholds
Oxygen tension
Initial and final intracellular oxygen partial pressure during deoxygenation
 PO2 mmHg
Mean corpuscular volume
Patient-specific erythrocyte volume
 MCV fL
Mean corpuscular hemoglobin concentration
Intracellular total hemoglobin concentration
 MCHC g/dL
Hemoglobin composition
Mole fractions of HbS, HbF, HbA, and other hemoglobin variants
 Hb_fraction fraction
Nucleation delay time
Delay before steady homogeneous HbS nucleation
 tau_d s
Sickled red-cell fraction
Fraction of modeled cells meeting the fiber-based sickling criterion
 sickled_fraction fraction
Pathograph links
Hemoglobin Polymerization recapitulates fidelity: moderate Simulates oxygen-dependent HbS nucleation and fiber growth using classical nucleation theory and chemical rate laws.
Limitations: HbS nucleus structure is not experimentally known, so the nucleation barrier and related prefactors rely on approximations and fitted values.
Red Blood Cell Sickling measures fidelity: moderate Converts simulated intracellular fiber-bundle growth into sickling time and the predicted fraction of sickled erythrocytes.
Limitations: Predictions depend strongly on patient-specific hemoglobin distributions, composition, and mean cell volume; missing inputs were sometimes replaced by assumed population values, and oxygen tension was modeled as spatially uniform.
Findings
Model sensitivity identified HbS solubility, the nucleation-rate prefactor, and oxygen affinity as dominant determinants of polymerization.
Show evidence (1 reference)
PMID:31457104 SUPPORT Computational
"Global sensitivity analysis on the kinetic parameters in the model revealed that the solubility, nucleation rate prefactor, and oxygen affinity are quantities that dictate HbS polymerization."
Directly reports the global sensitivity result.
The model was checked against prior in-vivo and in-vitro sickling data and produced drug-effect estimates consistent with recent screening assays.
Show evidence (1 reference)
PMID:31457104 SUPPORT Computational
"We validated this model by comparing its predictability against prior in vivo and in vitro experimental results. We used the model to quantify the efficacy of sickling inhibitors and obtain results consistent with recent screening assays."
Describes the validation comparisons and inhibitor-screen concordance.
Curated directly from the paper and supplementary equations; no exact code repository was identified. This is not a clinically validated digital twin: patient-specific inputs improve individual simulations, but prospective prognosis and dosing claims require further experimental validation.
Show evidence (1 reference)
PMID:31457104 SUPPORT Computational
"Thus, we developed a kinetic model based on the classical nucleation theory to examine the effectiveness of potential anti-sickling drug candidates."
Directly identifies the kinetic theory and therapeutic purpose.
{ }

Source YAML

click to show 
name: Sickle Cell Disease
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Sickle cell disease is caused by a glutamate-to-valine substitution at position 6 of beta-globin (HBB), producing hemoglobin S.
  On deoxygenation, hemoglobin S polymerizes into rigid fibers that deform red cells into the sickle shape, shortening their lifespan and causing chronic hemolytic anemia.
  Sickled cells adhere to endothelium and occlude the microcirculation, producing painful vaso-occlusive crises, nitric-oxide-depleting hemolysis, and progressive multiorgan damage.
category: Mendelian
parents:
- Hematological Disease
- Genetic Disease
disease_term:
  preferred_term: sickle cell disease
  term:
    id: MONDO:0011382
    label: sickle cell disease
gene_sets:
- gene_set: MYGENESET:JISON_SICKLE_CELL_DISEASE_UP
  relationship: DISEASE_SIGNATURE
  note: >-
    MSigDB sickle cell disease up-regulated expression signature (Jison et al.).
- gene_set: MYGENESET:JISON_SICKLE_CELL_DISEASE_DN
  relationship: DISEASE_SIGNATURE
  note: >-
    MSigDB sickle cell disease down-regulated expression signature (Jison et al.).
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0011382
      label: sickle cell disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:232
    mapping_justification: >-
      Orphanet's cross-reference table lists "MONDO:0011382 | Exact" for the
      ORPHA:232 sickle cell anemia structured record.
    consistency:
    - reference: ORPHA:232
      consistent: CONSISTENT
      notes: "MONDO:0011382 | Exact"
external_assertions:
- name: Orphanet sickle cell anemia structured record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:232
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=232
  description: >-
    Orphanet curates ORPHA:232 as the sickle cell anemia record, a severe
    homozygous HbS form within sickle cell disease, and provides exact
    cross-references to this entry's MONDO identifier plus OMIM, MeSH, MedDRA,
    UMLS, and other registry identifiers.
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:232  Sickle cell anemia"
    explanation: >-
      The Orphanet structured record heading identifies ORPHA:232 as the sickle
      cell anemia disease record.
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0011382 | Exact"
    explanation: >-
      Orphanet maps ORPHA:232 exactly to the MONDO disease identifier used by
      this entry.
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:603903 | Exact"
    explanation: Orphanet lists OMIM:603903 as an exact cross-reference.
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MeSH:D000755 | Exact"
    explanation: Orphanet lists MeSH:D000755 as an exact cross-reference.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Orphanet records sickle cell anemia as autosomal recessive, consistent with
    disease from biallelic pathogenic HBB alleles.
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "- Autosomal recessive"
    explanation: Orphanet directly records autosomal recessive inheritance.
prevalence:
- population: Global population, 2021
  percentage: 7.74 million people living with sickle cell disease
  notes: >-
    Global Burden of Disease 2021 estimates show substantial worldwide living
    prevalence, with highest burden in sub-Saharan Africa and increasing total
    case counts over time.
  evidence:
  - reference: PMID:37331373
    reference_title: "Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The number of people living with sickle cell disease globally increased by 41·4% (38·3-44·9), from 5·46 million (4·62-6·45) in 2000 to 7·74 million (6·51-9·2) in 2021.
    explanation: >-
      This GBD 2021 systematic analysis provides the best current global living
      prevalence estimate for sickle cell disease.
- population: Live births in 11 US Sickle Cell Data Collection states, 2016-2020
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 48.3
  percentage: 4.83 per 10,000 live births (1 in 2,070)
  notes: >-
    In the same surveillance dataset, birth prevalence among non-Hispanic Black
    newborns was 28.54 per 10,000 live births (1 in 350), showing the marked
    population-specific burden of disease in the United States.
  evidence:
  - reference: PMID:38547025
    reference_title: "Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births and 28.54 per 10,000 (one in every 350) non-Hispanic Black newborns.
    explanation: >-
      This multistate newborn-screening analysis provides a contemporary
      population-based US birth-prevalence estimate for sickle cell disease.
- population: Europe (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: 1-5 per 10,000
  notes: >-
    Orphanet classifies European point prevalence for sickle cell anemia in the
    1-5 per 10,000 band.
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Europe | Point prevalence | PMID:2019"
    explanation: >-
      Orphanet's epidemiology table provides this European point-prevalence
      class.
- population: United States (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: 1-5 per 10,000
  notes: >-
    Orphanet classifies United States point prevalence for sickle cell anemia in
    the 1-5 per 10,000 band.
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | United States | Point prevalence | PMID:20331952,INST"
    explanation: >-
      Orphanet's epidemiology table provides this United States point-prevalence
      class.
- population: United States live births (Orphanet)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: 1-5 per 10,000 live births
  notes: >-
    Orphanet classifies United States birth prevalence for sickle cell anemia in
    the 1-5 per 10,000 live-birth band.
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | United States | Prevalence at birth | PMID:17183567"
    explanation: >-
      Orphanet's epidemiology table provides this United States
      prevalence-at-birth class.
progression:
- phase: Onset
  age_range: All ages
  notes: Orphanet records onset across all ages for sickle cell anemia.
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet records all ages as the age-of-onset category.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_hbs_polymerization_vasoocclusion_model
  hypothesis_label: Canonical HbS Polymerization and Vaso-Occlusion Model
  status: CANONICAL
  description: >-
    Biallelic HBB pathogenic variants (most commonly βS/βS) produce hemoglobin S, which polymerizes upon deoxygenation into rigid intracellular fibers that deform erythrocytes into the characteristic sickle shape. Sickle erythrocytes show reduced deformability, increased adhesion to endothelium and leukocytes, and shortened survival, producing chronic hemolytic anemia and recurrent vaso-occlusive episodes. Downstream consequences include painful crises, acute chest syndrome, stroke, splenic infarction, end-organ damage (kidney, lung, retina, bone), and chronic inflammation driven by free heme and reactive oxygen species.
  notes: >-
    Retained as CANONICAL. The 2026 openscientist
    hypothesis-search report
    (kb/hypotheses/Sickle_Cell_Disease/canonical_hbs_polymerization_vasoocclusion_model)
    found the model strongly supported with mandatory qualifications.
    Most decisive evidence: CRISPR-Cas9 gene therapy (exa-cel) achieves
    97% freedom from severe VOCs by reactivating HbF to inhibit HbS
    polymerization — definitive that polymerization is the rate-limiting
    upstream event. Biophysical foundations (double-nucleation kinetics,
    extreme HbS-concentration dependence of polymerization delay) are
    among the most rigorously characterized in molecular medicine. Three
    qualifications: (1) vaso-occlusion is multicellular (endothelium,
    neutrophil, platelet, RBC adhesion), not purely RBC; (2) chronic
    hemolysis-driven oxidative stress and NO depletion drive
    pulmonary/renal end-organ damage independent of acute occlusion;
    (3) chronic inflammation persists post-HbF-reactivation, partly
    self-sustaining.
  evidence:
  - reference: PMID:29614632
    reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
    explanation: >
      Canonical mechanism review used as the seed reference for the
      hypothesis-search deep-research run.
pathophysiology:
- name: Hemoglobin Polymerization
  description: >
    Deoxygenated HbS polymerizes into rigid fibers, deforming red
    blood cells into sickle shape. HbS has glutamic acid to valine
    substitution at position 6 of beta-globin.
  biological_processes:
  - preferred_term: protein polymerization
    term:
      id: GO:0051258
      label: protein polymerization
  - preferred_term: response to hypoxia
    term:
      id: GO:0001666
      label: response to hypoxia
  downstream:
  - target: Red Blood Cell Sickling
    description: HbS polymer formation deforms erythrocytes and drives sickling.
  evidence:
  - reference: PMID:29614632
    reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
    explanation: HbS polymerization is concentration-dependent and leads to sickling.
  - reference: PMID:3965046
    reference_title: "Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes."
    supports: SUPPORT
    snippet: Our results support the hypothesis that the intracellular polymerization of HbS is the primary determinant of the severity of both anemia and clinical symptomatology in the sickle hemoglobinopathies.
    explanation: Establishes HbS polymerization as the primary determinant of clinical severity in sickling syndromes.
- name: Red Blood Cell Sickling
  description: >
    Sickled RBCs are rigid and fragile, leading to hemolytic anemia
    and shortened RBC lifespan (10-20 days vs normal 120 days).
  cell_types:
  - preferred_term: Red Blood Cell
    term:
      id: CL:0000232
      label: erythrocyte
  biological_processes:
  - preferred_term: erythrocyte homeostasis
    term:
      id: GO:0034101
      label: erythrocyte homeostasis
  - preferred_term: positive regulation of erythrocyte clearance
    term:
      id: GO:0034108
      label: positive regulation of erythrocyte clearance
  downstream:
  - target: Vaso-Occlusion
    description: Rigid sickled erythrocytes increase microvascular obstruction and endothelial interactions.
  - target: Chronic Hemolysis
    description: Repeated membrane injury promotes erythrocyte destruction and clearance.
  evidence:
  - reference: PMID:29614632
    reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In double heterozygosis for Hb S and C (SC disease) dehydration is the determining factor in disease pathophysiology."
    explanation: Cell dehydration promotes sickling and fragility of red blood cells.
- name: Vaso-Occlusion
  description: >
    Sickled cells adhere to vascular endothelium and obstruct
    microcirculation, causing tissue ischemia and pain crises.
    Inflammation amplifies adhesion.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: leukocyte adhesion to vascular endothelial cell
    term:
      id: GO:0061756
      label: leukocyte adhesion to vascular endothelial cell
  - preferred_term: positive regulation of cell adhesion
    term:
      id: GO:0045785
      label: positive regulation of cell adhesion
  downstream:
  - target: Pain Crises
    description: Microvascular obstruction causes ischemic vaso-occlusive pain episodes.
  - target: Chronic Organ Damage
    description: Recurrent vaso-occlusion causes ischemia-reperfusion injury in end organs.
  - target: Acute Chest Syndrome
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Chest Pain
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Stroke
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Priapism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Leg Ulcers
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Avascular Necrosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Osteomyelitis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Finger Dactylitis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:24277079
    reference_title: "Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "intravascular hemolysis in SCD releases heme that activates endothelial TLR4 signaling leading to WPB degranulation, NF-κB activation, and vaso-occlusion."
    explanation: Heme released from hemolysis triggers TLR4 signaling on endothelial cells, leading to Weibel-Palade body degranulation and release of P-selectin and von Willebrand factor, which promote adhesion and vaso-occlusion.
- name: Chronic Hemolysis
  description: >
    Intravascular hemolysis releases free hemoglobin, scavenging
    nitric oxide and causing endothelial dysfunction, pulmonary
    hypertension, and stroke risk.
  biological_processes:
  - preferred_term: nitric oxide metabolic process
    term:
      id: GO:0046209
      label: nitric oxide metabolic process
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  downstream:
  - target: Chronic Organ Damage
    description: Nitric oxide depletion and oxidative stress drive progressive endothelial and tissue injury.
  - target: Chronic Hemolytic Anemia
    description: Sustained erythrocyte destruction contributes to chronic hemolytic anemia.
  - target: Jaundice
    causal_link_type: DIRECT
  - target: Pigment Gallstones
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Reticulocytosis
    causal_link_type: DIRECT
  - target: Pulmonary Arterial Hypertension
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:15998894
    reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
    supports: SUPPORT
    snippet: "hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."
    explanation: Hemolysis releases both arginase (which depletes L-arginine, the substrate for nitric oxide synthesis) and free hemoglobin (which directly scavenges nitric oxide), leading to endothelial dysfunction and pulmonary hypertension.
  - reference: PMID:15998894
    reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
    supports: SUPPORT
    snippet: "The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease."
    explanation: Low arginine bioavailability due to increased arginase activity is directly associated with pulmonary hypertension severity and mortality risk in SCD patients.
- name: Chronic Organ Damage
  description: >
    Repeated vaso-occlusion and ischemia-reperfusion injury cause
    progressive damage to spleen, kidneys, lungs, and brain.
  biological_processes:
  - preferred_term: response to ischemia
    term:
      id: GO:0002931
      label: response to ischemia
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  downstream:
  - target: Splenic Sequestration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Abnormality of the Spleen
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Recurrent Infections
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Thrombocytosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Chronic Kidney Disease
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Retinopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Pulmonary Arterial Hypertension
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Osteoporosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- name: Pain Crises
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Acute vaso-occlusive episodes
  phenotype_term:
    preferred_term: Pain Crisis
    term:
      id: HP:0012531
      label: Pain
  evidence:
  - reference: PMID:24277079
    reference_title: "Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Heme rapidly (5 minutes) mobilized Weibel-Palade body (WPB) P-selectin and VWF onto EC and vessel wall surfaces and activated EC nuclear factor κB (NF-κB)."
    explanation: Heme-induced rapid release of adhesion molecules (P-selectin and von Willebrand factor) triggers vaso-occlusion, which causes pain crises in sickle cell disease.
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012531 | Pain | Very frequent (99-80%)"
    explanation: >-
      Orphanet independently records pain as a very frequent HPO phenotype of
      sickle cell anemia.
- name: Chronic Hemolytic Anemia
  category: Hematologic
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Chronic hemolytic anemia
    term:
      id: HP:0004870
      label: Chronic hemolytic anemia
  evidence:
  - reference: PMID:15998894
    reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
    supports: SUPPORT
    snippet: "hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase"
    explanation: Chronic hemolysis is a hallmark feature of sickle cell disease.
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004870 | Chronic hemolytic anemia | Obligate (100%)"
    explanation: >-
      Orphanet records chronic hemolytic anemia as an obligate phenotype of
      sickle cell anemia.
- name: Jaundice
  category: Hematologic
  frequency: FREQUENT
  notes: From chronic hemolysis
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000952 | Jaundice | Frequent (79-30%)"
    explanation: Orphanet records jaundice as a frequent phenotype.
- name: Splenic Sequestration
  category: Hematologic
  frequency: OCCASIONAL
  notes: Medical emergency in children
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- name: Abnormality of the Spleen
  category: Hematologic
  frequency: FREQUENT
  notes: Broad Orphanet spleen phenotype complementing specific splenic sequestration risk.
  phenotype_term:
    preferred_term: Abnormality of the spleen
    term:
      id: HP:0001743
      label: Abnormality of the spleen
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001743 | Abnormality of the spleen | Frequent (79-30%)"
    explanation: Orphanet records spleen abnormality as a frequent phenotype.
- name: Acute Chest Syndrome
  category: Respiratory
  frequency: OCCASIONAL
  notes: Leading cause of death
  phenotype_term:
    preferred_term: Respiratory Distress
    term:
      id: HP:0002098
      label: Respiratory distress
  evidence:
  - reference: PMID:24620350
    reference_title: "Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Sickle cell disease (SCD) is characterized by recurring episodes of vascular occlusion in which neutrophil activation plays a major role. The disease is associated with chronic hemolysis with elevated cell-free hemoglobin and heme."
    explanation: Neutrophil activation and hemolysis contribute to vascular occlusion and acute complications like acute chest syndrome.
  - reference: PMID:24620350
    reference_title: "Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we have identified a novel role for heme in the induction of neutrophil extracellular trap (NET) formation in SCD. NETs are decondensed chromatin decorated by granular enzymes and are released by activated neutrophils."
    explanation: Heme triggers neutrophil extracellular trap formation, which contributes to acute lung injury and acute chest syndrome in sickle cell disease.
- name: Chest Pain
  category: Respiratory
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100749 | Chest pain | Frequent (79-30%)"
    explanation: Orphanet records chest pain as a frequent phenotype.
- name: Stroke
  category: Neurological
  frequency: OCCASIONAL
  notes: Children and adults at risk
  phenotype_term:
    preferred_term: Ischemic Stroke
    term:
      id: HP:0002140
      label: Ischemic stroke
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002140 | Ischemic stroke | Occasional (29-5%)"
    explanation: Orphanet records ischemic stroke as an occasional phenotype.
- name: Priapism
  category: Urological
  frequency: OCCASIONAL
  notes: In males
  phenotype_term:
    preferred_term: Priapism
    term:
      id: HP:0200023
      label: Priapism
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200023 | Priapism | Occasional (29-5%)"
    explanation: Orphanet records priapism as an occasional phenotype.
- name: Leg Ulcers
  category: Dermatological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Skin Ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200042 | Skin ulcer | Occasional (29-5%)"
    explanation: Orphanet records skin ulcer as an occasional phenotype.
- name: Recurrent Infections
  category: Immunologic
  frequency: VERY_FREQUENT
  notes: Functional asplenia and impaired splenic clearance increase infection risk.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002719 | Recurrent infections | Very frequent (99-80%)"
    explanation: Orphanet records recurrent infections as a very frequent phenotype.
- name: Pigment Gallstones
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Chronic hemolysis increases bilirubin turnover and pigment gallstone risk.
  phenotype_term:
    preferred_term: Pigment gallstones
    term:
      id: HP:0011981
      label: Pigment gallstones
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011981 | Pigment gallstones | Frequent (79-30%)"
    explanation: Orphanet records pigment gallstones as a frequent phenotype.
- name: Thrombocytosis
  category: Hematologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Thrombocytosis
    term:
      id: HP:0001894
      label: Thrombocytosis
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001894 | Thrombocytosis | Frequent (79-30%)"
    explanation: Orphanet records thrombocytosis as a frequent phenotype.
- name: Reticulocytosis
  category: Hematologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Reticulocytosis
    term:
      id: HP:0001923
      label: Reticulocytosis
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001923 | Reticulocytosis | Frequent (79-30%)"
    explanation: Orphanet records reticulocytosis as a frequent phenotype.
- name: Avascular Necrosis
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Vaso-occlusion can compromise bone blood supply.
  phenotype_term:
    preferred_term: Avascular necrosis
    term:
      id: HP:0010885
      label: Avascular necrosis
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010885 | Avascular necrosis | Frequent (79-30%)"
    explanation: Orphanet records avascular necrosis as a frequent phenotype.
- name: Osteoporosis
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000939 | Osteoporosis | Frequent (79-30%)"
    explanation: Orphanet records osteoporosis as a frequent phenotype.
- name: Osteomyelitis
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Osteomyelitis
    term:
      id: HP:0002754
      label: Osteomyelitis
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002754 | Osteomyelitis | Frequent (79-30%)"
    explanation: Orphanet records osteomyelitis as a frequent phenotype.
- name: Chronic Kidney Disease
  category: Renal
  frequency: FREQUENT
  notes: Recurrent vaso-occlusion and hemolysis contribute to sickle nephropathy.
  phenotype_term:
    preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012622 | Chronic kidney disease | Frequent (79-30%)"
    explanation: Orphanet records chronic kidney disease as a frequent phenotype.
- name: Retinopathy
  category: Ophthalmologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Retinopathy
    term:
      id: HP:0000488
      label: Retinopathy
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000488 | Retinopathy | Frequent (79-30%)"
    explanation: Orphanet records retinopathy as a frequent phenotype.
- name: Pulmonary Arterial Hypertension
  category: Cardiovascular
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002092 | Pulmonary arterial hypertension | Occasional (29-5%)"
    explanation: >-
      Orphanet records pulmonary arterial hypertension as an occasional
      phenotype.
- name: Finger Dactylitis
  category: Musculoskeletal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Finger dactylitis
    term:
      id: HP:0031090
      label: Finger dactylitis
  evidence:
  - reference: ORPHA:232
    reference_title: "Sickle cell anemia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031090 | Finger dactylitis | Occasional (29-5%)"
    explanation: Orphanet records finger dactylitis as an occasional phenotype.
biochemical:
- name: Hemoglobin
  presence: Decreased
  context: "Chronic anemia, Hb typically 6-9 g/dL"
  readouts:
  - target: Chronic Hemolysis
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: MONITORING
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-078
    - FDA-SE-pediatric-noncancer-054
    interpretation: >-
      Lower hemoglobin concentration reflects anemia from ongoing hemolysis and
      marrow compensation limits.
  biomarker_term:
    preferred_term: hemoglobin measurement
    term:
      id: NCIT:C64848
      label: Hemoglobin Measurement
  evidence:
  - reference: PMID:31199090
    reference_title: "A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary end point was the percentage of participants who had a
      hemoglobin response, which was defined as an increase of more than 1.0 g
      per deciliter from baseline at week 24 in the intention-to-treat analysis.
    explanation: >-
      This phase 3 SCD trial used hemoglobin response as a blood biomarker
      endpoint, supporting hemoglobin concentration as a clinically measured
      biomarker in SCD.
  - reference: PMID:15998894
    reference_title: "Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease."
    supports: SUPPORT
    snippet: "hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."
    explanation: Chronic hemolysis releases free hemoglobin, contributing to anemia.
- name: Reticulocytes
  presence: Elevated
  context: Compensatory increased production
  readouts:
  - target: Chronic Hemolysis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Elevated reticulocytes reflect marrow response to red-cell destruction in
      chronic hemolysis.
  biomarker_term:
    preferred_term: reticulocyte count
    term:
      id: NCIT:C51947
      label: Reticulocyte Count
  evidence:
  - reference: PMID:16291595
    reference_title: "Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a cohort of 213 patients with sickle cell disease, we found
      statistically significant associations of steady-state LDH with low levels
      of hemoglobin and haptoglobin and high levels of reticulocytes,
      bilirubin, plasma hemoglobin, aspartate aminotransferase, arginase, and
      soluble adhesion molecules.
    explanation: >-
      This SCD cohort study supports elevated reticulocytes as part of the
      hemolysis-associated biomarker profile.
- name: Bilirubin
  presence: Elevated
  context: Indirect, from hemolysis
  readouts:
  - target: Chronic Hemolysis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Higher indirect bilirubin reflects heme catabolism from accelerated
      red-cell breakdown.
  biomarker_term:
    preferred_term: indirect bilirubin measurement
    term:
      id: NCIT:C64483
      label: Indirect Bilirubin Measurement
  evidence:
  - reference: PMID:31199090
    reference_title: "A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At week 24, the 1500-mg voxelotor group had significantly greater
      reductions from baseline in the indirect bilirubin level and percentage of
      reticulocytes than the placebo group.
    explanation: >-
      This phase 3 SCD trial used indirect bilirubin as a hemolysis biomarker
      that changed with treatment.
- name: LDH
  presence: Elevated
  context: Hemolysis marker
  readouts:
  - target: Chronic Hemolysis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    interpretation: >-
      Higher LDH reflects intravascular hemolysis and has been associated with
      hemolysis-linked vasculopathy risk.
  biomarker_term:
    preferred_term: lactate dehydrogenase measurement
    term:
      id: NCIT:C64855
      label: Lactate Dehydrogenase Measurement
  synonyms:
  - lactate dehydrogenase
  evidence:
  - reference: PMID:16291595
    reference_title: "Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We hypothesized that serum LDH may represent a convenient biomarker of
      intravascular hemolysis and NO bioavailability, characterizing a clinical
      subphenotype of hemolysis-associated vasculopathy.
    explanation: >-
      This human SCD cohort paper directly evaluates serum LDH as a biomarker of
      intravascular hemolysis and nitric-oxide bioavailability.
- name: HbS
  presence: Present
  context: "Greater than 50% on hemoglobin electrophoresis"
  readouts:
  - target: Hemoglobin Polymerization
    relationship: CORRELATES_WITH
    direction: THRESHOLD_DEPENDENT
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      HbS fraction identifies the polymerizing hemoglobin substrate; risk
      depends on genotype, oxygenation, concentration, and modifying hemoglobins.
  biomarker_term:
    preferred_term: hemoglobin S measurement
    term:
      id: NCIT:C122123
      label: Hemoglobin S Measurement
  synonyms:
  - sickle hemoglobin
  evidence:
  - reference: PMID:31199090
    reference_title: "A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deoxygenated sickle hemoglobin (HbS) polymerization drives the
      pathophysiology of sickle cell disease. Therefore, direct inhibition of
      HbS polymerization has potential to favorably modify disease outcomes.
      Voxelotor is an HbS polymerization inhibitor.
    explanation: >-
      This phase 3 SCD trial frames HbS polymerization as the proximal disease
      biochemical process targeted by therapy.
- name: Fetal Hemoglobin
  presence: Variable
  context: >-
    Higher HbF modifies SCD severity and is induced by therapies such as
    hydroxyurea.
  readouts:
  - target: Hemoglobin Polymerization
    relationship: CORRELATES_WITH
    direction: NEGATIVE
    endpoint_context: PHARMACODYNAMIC
    interpretation: >-
      Higher HbF is associated with reduced HbS polymerization and can serve as
      a pharmacodynamic readout for HbF-inducing therapies.
  biomarker_term:
    preferred_term: hemoglobin F measurement
    term:
      id: NCIT:C92262
      label: Hemoglobin F Measurement
  synonyms:
  - HbF
  evidence:
  - reference: PMID:18667698
    reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Interindividual variation in fetal hemoglobin (HbF) expression is a known
      and potentially heritable modifier of SCD severity. High HbF levels are
      correlated with reduced morbidity and mortality.
    explanation: >-
      This human genetic association study supports HbF level as a clinically
      meaningful modifier biomarker in SCD.
  - reference: PMID:7715639
    reference_title: "Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a previous open-label study of hydroxyurea therapy, the synthesis of
      fetal hemoglobin increased in most patients with sickle cell anemia, with
      only mild myelotoxicity.
    explanation: >-
      This sickle-cell anemia trial background supports HbF induction as a
      treatment-linked biomarker.
computational_models:
- name: Zheng multiscale QSP model of autologous gene therapy
  description: >-
    Deterministic ordinary-differential-equation model coupling hematopoietic
    stem-cell engraftment, erythroid differentiation, red-cell turnover,
    globin assembly, and oxygen-regulated erythropoiesis. Healthy and SCD
    parameterizations are extended with myeloablative preconditioning and
    transplantation of CD34-positive cells expressing an anti-sickling
    gamma-globin.
  model_type: KINETIC
  model_id: Zheng-SCD-QSP-2021
  model_format: ODE equations and parameters in the article and supporting information
  publication: PMID:34139105
  modeled_mechanisms:
  - target: Chronic Hemolysis
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the shortened red-cell lifespan and compensatory erythropoietic
      state used to distinguish the SCD and healthy steady states.
    limitations: >-
      Hemolysis is represented through a fixed mean red-cell lifespan rather
      than explicit intravascular and extravascular destruction mechanisms.
  - target: Red Blood Cell Sickling
    relationship: PERTURBS
    fidelity: MODERATE
    description: >-
      Simulates replacement of HbS-containing cells by longer-lived transduced
      cells expressing an anti-sickling hemoglobin after autologous gene therapy.
    limitations: >-
      The model predicts hemoglobin composition and a non-sickled-cell fraction
      but does not explicitly simulate HbS nucleation, fiber growth, membrane
      deformation, vaso-occlusion, or organ injury.
  variables:
  - name: Initial transduced CD34-positive cell dose
    dataset_identifier: initial_dose
    description: Number of autologous progenitor cells infused after preconditioning
    unit: cells
  - name: Long-term hematopoietic stem-cell fraction
    dataset_identifier: LT-HSC_fraction
    description: Fraction of the infused dose capable of stable long-term engraftment
    unit: fraction
  - name: Mean vector copy number
    dataset_identifier: VCN
    description: Model proxy for the fraction of infused cells carrying the therapeutic vector
    unit: copies/cell
  - name: Preconditioning depletion
    dataset_identifier: preconditioning
    description: Fractional depletion of endogenous hematopoietic progenitor pools
    unit: fraction
  - name: Anti-sickling hemoglobin
    dataset_identifier: HbNew
    description: Peripheral-blood concentration of the modeled therapeutic hemoglobin
    unit: g/dL
  - name: Transduced red blood cells
    dataset_identifier: transduced_RBC
    description: Circulating red cells derived from transduced progenitors
    unit: cells
  evidence:
  - reference: PMID:34139105
    reference_title: "A systems pharmacology model for gene therapy in sickle cell disease."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We used ordinary differential equations to model RBC production from progenitor cells in the bone marrow, and hemoglobin assembly from its constituent globin monomers."
    explanation: >-
      Establishes the mathematical form and the coupled erythropoiesis and
      hemoglobin-assembly scope of the model.
  findings:
  - statement: >-
      Simulated reconstitution is biphasic: short-lived progenitors generate an
      early wave of transduced red cells, while long-term stem-cell engraftment
      sustains later production.
    evidence:
    - reference: PMID:34139105
      reference_title: "A systems pharmacology model for gene therapy in sickle cell disease."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "Post-treatment dynamics show an early phase of reconstitution due to short lived stem cells, followed by a sustained RBC production from stable engraftment of long-term stem cells."
      explanation: Directly reports the model's two predicted reconstitution phases.
  - statement: >-
      Initial transduced-cell dose and myeloablative preconditioning intensity
      were the strongest positive determinants of modeled long-term outcome.
    evidence:
    - reference: PMID:34139105
      reference_title: "A systems pharmacology model for gene therapy in sickle cell disease."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "The initial dose of transduced stem cells, and the intensity of myeloablative bone marrow preconditioning are predicted to most positively impact long-term outcomes."
      explanation: Directly states the principal long-term sensitivity result.
  notes: >-
    Curated from the publication and supporting equations; no exact deposited
    implementation was identified. Important assumptions include deterministic
    population averages, at most one vector copy per cell, fixed fractional
    progenitor depletion, immediate marrow homing, omission of non-erythroid
    hematopoiesis and iron/heme handling, and empirical oxygen feedback.
- name: Lu stochastic kinetic model of HbS polymerization and erythrocyte sickling
  description: >-
    Patient- and organ-parameterized model coupling oxygen-dependent HbS
    solubility, homogeneous and heterogeneous nucleation, fiber growth, and a
    mechanical criterion for red-cell sickling. Inputs include oxygen tension,
    deoxygenation time, temperature, cell volume, hemoglobin concentration, and
    hemoglobin composition.
  model_type: KINETIC
  model_id: Lu-HbS-sickling-2019
  model_format: Stochastic kinetic equations and parameters in the article and supplementary materials
  publication: PMID:31457104
  modeled_mechanisms:
  - target: Hemoglobin Polymerization
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Simulates oxygen-dependent HbS nucleation and fiber growth using classical
      nucleation theory and chemical rate laws.
    limitations: >-
      HbS nucleus structure is not experimentally known, so the nucleation
      barrier and related prefactors rely on approximations and fitted values.
  - target: Red Blood Cell Sickling
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      Converts simulated intracellular fiber-bundle growth into sickling time
      and the predicted fraction of sickled erythrocytes.
    limitations: >-
      Predictions depend strongly on patient-specific hemoglobin distributions,
      composition, and mean cell volume; missing inputs were sometimes replaced
      by assumed population values, and oxygen tension was modeled as spatially
      uniform.
  variables:
  - name: Oxygen tension
    dataset_identifier: PO2
    description: Initial and final intracellular oxygen partial pressure during deoxygenation
    unit: mmHg
  - name: Mean corpuscular volume
    dataset_identifier: MCV
    description: Patient-specific erythrocyte volume
    unit: fL
  - name: Mean corpuscular hemoglobin concentration
    dataset_identifier: MCHC
    description: Intracellular total hemoglobin concentration
    unit: g/dL
  - name: Hemoglobin composition
    dataset_identifier: Hb_fraction
    description: Mole fractions of HbS, HbF, HbA, and other hemoglobin variants
    unit: fraction
  - name: Nucleation delay time
    dataset_identifier: tau_d
    description: Delay before steady homogeneous HbS nucleation
    unit: s
  - name: Sickled red-cell fraction
    dataset_identifier: sickled_fraction
    description: Fraction of modeled cells meeting the fiber-based sickling criterion
    unit: fraction
  evidence:
  - reference: PMID:31457104
    reference_title: "Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Thus, we developed a kinetic model based on the classical nucleation theory to examine the effectiveness of potential anti-sickling drug candidates."
    explanation: Directly identifies the kinetic theory and therapeutic purpose.
  findings:
  - statement: >-
      Model sensitivity identified HbS solubility, the nucleation-rate
      prefactor, and oxygen affinity as dominant determinants of polymerization.
    evidence:
    - reference: PMID:31457104
      reference_title: "Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "Global sensitivity analysis on the kinetic parameters in the model revealed that the solubility, nucleation rate prefactor, and oxygen affinity are quantities that dictate HbS polymerization."
      explanation: Directly reports the global sensitivity result.
  - statement: >-
      The model was checked against prior in-vivo and in-vitro sickling data and
      produced drug-effect estimates consistent with recent screening assays.
    evidence:
    - reference: PMID:31457104
      reference_title: "Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: "We validated this model by comparing its predictability against prior in vivo and in vitro experimental results. We used the model to quantify the efficacy of sickling inhibitors and obtain results consistent with recent screening assays."
      explanation: Describes the validation comparisons and inhibitor-screen concordance.
  notes: >-
    Curated directly from the paper and supplementary equations; no exact code
    repository was identified. This is not a clinically validated digital twin:
    patient-specific inputs improve individual simulations, but prospective
    prognosis and dosing claims require further experimental validation.
genetic:
- name: HBB
  gene_term:
    preferred_term: HBB
    term:
      id: hgnc:4827
      label: HBB
  association: Causative
  notes: Glu6Val mutation (rs334)
  evidence:
  - reference: PMID:18667698
    reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
    supports: SUPPORT
    snippet: "Sickle cell disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mortality."
    explanation: Confirms SCD is a monogenic blood disorder caused by HBB mutations.
- name: BCL11A
  gene_term:
    preferred_term: BCL11A
    term:
      id: hgnc:13221
      label: BCL11A
  association: Modifier
  notes: Regulates HbF levels
  evidence:
  - reference: PMID:18667698
    reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
    supports: SUPPORT
    snippet: "Common single nucleotide polymorphisms (SNPs) at the BCL11A and HBS1L-MYB loci have been implicated previously in HbF level variation"
    explanation: BCL11A polymorphisms regulate fetal hemoglobin levels and modify sickle cell disease severity.
- name: HBS1L-MYB
  association: Modifier
  notes: Affects HbF levels
  evidence:
  - reference: PMID:18667698
    reference_title: "DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease."
    supports: SUPPORT
    snippet: "Together, common SNPs at the BCL11A, HBS1L-MYB, and beta-globin (HBB) loci account for >20% of the variation in HbF levels in SCD patients."
    explanation: HBS1L-MYB locus polymorphisms are major modifiers of HbF levels in sickle cell disease.
environmental:
- name: Dehydration
  exposure_term:
    preferred_term: dehydration
    term:
      id: XCO:0001602
      label: dehydration
  influences_mechanisms:
  - target: Hemoglobin Polymerization
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      An unusually exact exposure-to-node fit, and the reason is physical:
      polymerisation depends steeply on intracellular haemoglobin
      concentration, so removing water from the cell acts on this node
      directly rather than through anything in between. The cited sentence
      says exactly that.
    evidence:
    - reference: PMID:29614632
      reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Cell dehydration is a distinguishing characteristic of sickle cell disease and an important contributor to disease pathophysiology. Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
      explanation: >-
        States that because polymerisation depends uniquely on cellular
        haemoglobin S concentration, cell dehydration promotes polymerisation
        and sickling. Exposure, mechanism and node in one sentence.
  notes: Triggers sickling
  evidence:
  - reference: PMID:29614632
    reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cell dehydration is a distinguishing characteristic of sickle cell disease and an important contributor to disease pathophysiology. Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling."
    explanation: Dehydration increases intracellular HbS concentration, promoting sickling.
- name: Hypoxia
  influences_mechanisms:
  - target: Hemoglobin Polymerization
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Direct because the node itself is about deoxygenated haemoglobin S, so
      falling oxygen tension acts on it with nothing in between. Graded
      partial rather than supporting despite that tight fit, because the
      available sentence is about oxygen tension regulating ion transport
      pathways and never states that hypoxia promotes polymerisation. The
      directness comes from the node's own wording, not from the evidence.
    evidence:
    - reference: PMID:29614632
      reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Each of these pathways exhibit unique characteristics in regulation by oxygen tension, intracellular and extracellular environment"
      explanation: >-
        Reports that the ion transport pathways discussed are regulated by
        oxygen tension. It connects oxygen to the cell's water handling rather
        than to polymerisation at this node.
  notes: Promotes HbS polymerization
  evidence:
  - reference: PMID:29614632
    reference_title: "Sickle cell dehydration: Pathophysiology and therapeutic applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Each of these pathways exhibit unique characteristics in regulation by oxygen tension, intracellular and extracellular environment"
    explanation: Low oxygen tension affects ion transport pathways that contribute to sickling.
- name: Cold Exposure
  exposure_term:
    preferred_term: exposure to decreased temperature
    term:
      id: ECTO:0001057
      label: exposure to decreased temperature
  notes: >-
    Associated with vaso-occlusion. The human evidence is seasonal and
    correlational, with a small effect size; the causal step from cold exposure
    to vaso-occlusion has been shown directly only in a mouse model.
  evidence:
  - reference: PMID:34540479
    reference_title: Effect of Weather on Frequency of Vaso-Occlusive Crisis in Children With Sickle Cell Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Total episodes of VOC peaked during January (n=44), while they were lowest in July (n=16)."
    explanation: >-
      Human observational evidence that vaso-occlusive crises cluster in the
      coldest month and are least frequent in the warmest. PARTIAL because the
      study's own temperature correlation is weak, at r = -0.05, and a seasonal
      peak does not isolate cold from the other things that vary with season.
  - reference: PMID:37774369
    reference_title: Cold exposure induces vaso-occlusion and pain in sickle mice that depend on complement activation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Cold exposure induced more vaso-occlusion in nonhyperalgesic HbSS mice (33%) than in HbAA mice (11%) or HbSS mice left at room temperature (1%)."
    explanation: >-
      Establishes the causal step in a sickle mouse model, with both a genotype
      and a temperature control. Model-organism evidence, so it is paired with
      the human seasonal data rather than standing alone for a human claim.
- name: High Altitude
  notes: Low oxygen triggers crises
  evidence:
  - reference: PMID:7340130
    reference_title: Risk of altitude exposure in sickle cell disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The average risk of crisis was higher for both groups while in the mountains (37.9 percent and 56.6 percent, respectively) than it was during airplane travel (10.8 percent and 13.5 percent, respectively)."
    explanation: >-
      Quantifies painful-crisis risk by altitude exposure in patients with
      sickle cell disease, and shows it rises with the degree of hypoxaemia:
      mountain stays carry several times the risk of pressurised air travel.
  - reference: PMID:7340130
    reference_title: Risk of altitude exposure in sickle cell disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with sickle cell disease are at high risk of crisis in the mountains, and we advise those with intact spleens to breathe supplemental oxygen during air travel."
    explanation: >-
      The study's own conclusion, stated as a clinical recommendation, that
      altitude exposure is a crisis risk in this disease.
- name: Infections
  exposure_term:
    preferred_term: Infectious agent exposure
    term:
      id: ECTO:3000000
      label: exposure to organism
  notes: Common trigger for crises
  evidence:
  - reference: PMID:39568431
    reference_title: Infections in sickle cell disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with SCD have significant immunodeficiency and are more likely to suffer severe and life-threatening complications of infection, and additionally infections can trigger complications of SCD itself."
    explanation: >-
      States the two-way relationship this entry depends on: the disease raises
      susceptibility to infection, and infection in turn triggers complications
      of the disease. The second clause is the exposure claim made here.
treatments:
- name: Hydroxyurea
  description: Increases HbF, reduces pain crises, first-line disease-modifying therapy.
  evidence:
  - reference: PMID:7715639
    reference_title: "Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia."
    supports: SUPPORT
    snippet: "the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001)"
    explanation: Landmark RCT demonstrating hydroxyurea reduces painful crises by nearly half in sickle cell disease.
- name: Voxelotor
  description: >-
    HbS polymerization inhibitor formerly used to improve anemia; voluntarily
    withdrawn from worldwide markets in 2024 due to postmarketing safety
    concerns.
- name: Crizanlizumab
  description: >-
    P-selectin inhibitor for reducing vaso-occlusive crises; regulatory status
    is jurisdiction-dependent after EU authorization revocation was recommended
    in 2023 when STAND did not confirm benefit.
- name: L-Glutamine
  description: Reduces oxidative stress in RBCs.
- name: Blood Transfusions
  description: Chronic transfusions for stroke prevention, acute for severe anemia.
- name: Pain Management
  description: NSAIDs, opioids for acute crises.
- name: Penicillin Prophylaxis
  description: In children to prevent pneumococcal sepsis.
- name: Hematopoietic Stem Cell Transplant
  description: Curative option for selected patients.
- name: Gene Therapy
  description: >-
    Autologous gene therapy using multiple platforms (lentiviral, shmiR-BCL11A,
    CRISPR-Cas9, CRISPR-Cas12a, base-editing) for BCL11A-mediated fetal hemoglobin
    reactivation or altered hemoglobin synthesis. FDA-approved: exagamglogene autotemcel
    (exa-cel, CRISPR-Cas9) and lovotibeglogene autotemcel (lovo-cel, lentiviral).
    Reni-cel (CRISPR-Cas12a) and risto-cel (base editing) in advanced trials.
  evidence:
  - reference: PMID:38661449
    reference_title: "Exagamglogene Autotemcel for Severe Sickle Cell Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A."
    explanation: CRISPR-Cas9 gene editing of the BCL11A enhancer reactivates fetal hemoglobin, which prevents sickling.
  - reference: PMID:38661449
    reference_title: "Exagamglogene Autotemcel for Severe Sickle Cell Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more."
    explanation: In phase 3 clinical trials, exagamglogene autotemcel (exa-cel) eliminated vaso-occlusive crises in 97% of patients for 12+ months, demonstrating high therapeutic efficacy.
  - reference: PMID:42400217
    reference_title: "Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autologous gene therapy has emerged as a potential curative strategy, but trial efficacy must be interpreted together with mobilization, apheresis collection, manufacturing, conditioning, cost, fertility preservation, and long-term surveillance requirements."
    explanation: Systematic review confirms autologous gene therapy as emerging curative strategy while emphasizing treatment-delivery complexity and practical feasibility factors.
  - reference: PMID:42400217
    reference_title: "Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prospectively defined VF12 was 96.7% (29/30) in the exa-cel pivotal cohort, and severe VOE resolution was 100% (25/25) in the lovo-cel pivotal cohort; both products achieved transfusion independence in evaluable patients."
    explanation: Systematic review of 148 patients across 9 clinical programs shows exa-cel achieves 96.7% 12-month VOE-free survival and lovo-cel achieves 100% severe VOE resolution, with both achieving transfusion independence.
  - reference: PMID:42400217
    reference_title: "Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reni-cel and risto-cel added contemporary Cas12a and base-editing evidence, with early follow-up showing high HbF induction and few or no reported post-infusion VOEs, but follow-up was shorter, and endpoints were not pooled with pivotal VF12 cohorts."
    explanation: Newer CRISPR-Cas12a and base-editing platforms (reni-cel, risto-cel) demonstrate high fetal hemoglobin induction and early vaso-occlusive event freedom, expanding gene-therapy options beyond CRISPR-Cas9 and lentiviral approaches.
  - reference: PMID:42400217
    reference_title: "Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "certainty remains limited by single-arm designs, small samples, evolving protocols, and incomplete long-term follow-up"
    explanation: Systematic review notes current limitations in trial design, sample sizes, and incomplete follow-up data for gene therapy efficacy assessment.
  - reference: PMID:42400217
    reference_title: "Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Long-term safety, fertility, organ outcomes, reimbursement, and global scalability remain unresolved implementation barriers."
    explanation: Systematic review identifies unresolved long-term safety, fertility, reimbursement, and global scalability barriers to sustained gene therapy implementation in SCD.
  - reference: PMID:42008008
    reference_title: "Clinical outcomes of lentiviral vector gene therapy for sickle cell disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the 3 patients treated with the optimized protocol achieved higher and sustained gene marking (peak granulocyte VCNs, ∼0.5-2.0) and persistent HbAS3 expression. These patients experienced some reductions in vaso-occlusive crises and transfusion requirements, with 2 becoming transfusion independent."
    explanation: Phase 1/2 study of the Lenti/G-βAS3-FB lentiviral vector; the 3 patients treated with the optimized protocol achieved sustained gene marking and persistent HbAS3 expression, with reductions in vaso-occlusive crises and transfusion requirements and 2 of those 3 becoming transfusion independent.
  - reference: PMID:42008008
    reference_title: "Clinical outcomes of lentiviral vector gene therapy for sickle cell disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No insertional oncogenesis was observed."
    explanation: Lentiviral gene therapy shows favorable long-term safety profile with no insertional mutagenesis in phase 1/2 trial.
classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
datasets:
- accession: ega:EGAS00001000990
  title: Fetal hemoglobin in sickle cell disease patients from Tanzania
  description: Levels of fetal hemoglobin have been associated with differences in severity and outcome of sickle cell disease (SCD). While some genetic associations have been reported between SNPs and HbF level, little of the variance in the trait is explained, and most studies have focused on African American, rather than African samples. We have carried out a GWAS in a collection of SCD patients from Dar es Salaam, Tanzania. This sample represents a diverse, metropolitan collection of individuals from East Africa. Omni 2.5M genotypes and HbF levels (measured after 5 years of age) are available.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Sickle Cell Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: massive:MSV000093893
  title: Nontargeted plasma proteomics analysis uncovers candidate biomarkers for renal disease and pulmonary hypertension in patients with sickle cell disease
  description: Fifteen microliters of plasma from sickle cell disease patients, and pooled samples, were diluted with 5% deoxycholate and 10 mM DTT, followed by heating at 80 degC for 30 min, alkylation with 25 mM iodoacteamide and digestion with modified trypsin for 4 h at 37 degC. After acidification, samples were filtered.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Sickle Cell Disease"). Retrieved 2026-08-02.
- accession: dbgap:phs001466
  title: 'NHBLI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU)'
  description: Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS) within circulating erythrocytes resulting in hemolytic anemia, vascular occlusion, and end organ damage due to alterations in the shape and deformability of the cell membrane. The disease is inherited in an autosomal recessive pattern, and is most commonly caused by a single nucleotide substitution in the hemoglobin subunit beta (HBB) gene located on chromosome 11.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Sickle Cell Disease"). Retrieved 2026-08-02.
- accession: massive:MSV000092457
  title: Metabolic and Proteomic Changes in Sickle Cell Disease and thalassemia Mouse Splenic and Hepatic Macrophages and Peripheral Blood Mononuclear cells
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: MULTI_OMICS
  description: Sickle cell disease and Beta-thalassemia represent hemoglobinopathies arising from dysfunctional or under produced beta-globin chains, respectively. In both diseases, red blood cell injury and anemia are the impetus for end organ injury. Because persistent erythrophagocytosis is a hallmark of these genetic maladies it is critical to understand how macrophage phenotype polarizations in tissue compartments can inform on disease progression. Murine models of sickle cell disease and Beta-thalassemia allow for a basic understanding of mechanisms and provide for translation to human disease.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Sickle Cell Disease"). Retrieved 2026-08-02.
references:
- reference: DOI:10.1001/jama.2008.598
  title: Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
  findings: []
- reference: DOI:10.1001/jama.294.1.81
  title: Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease
  findings: []
- reference: DOI:10.1007/s00277-025-06216-1
  title: A review on disease modifying pharmacologic therapies for sickle cell disease
  findings: []
- reference: DOI:10.1016/j.bvth.2024.100015
  title: 'Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation'
  findings: []
- reference: DOI:10.1056/nejmoa2309676
  title: Exagamglogene Autotemcel for Severe Sickle Cell Disease
  findings: []
- reference: DOI:10.1080/17474086.2017.1327809
  title: 'Heme-mediated cell activation: the inflammatory puzzle of sickle cell anemia'
  findings: []
- reference: DOI:10.1182/blood-2013-04-495887
  title: Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease
  findings: []
- reference: DOI:10.1182/blood-2013-10-529982
  title: Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease
  findings: []
- reference: DOI:10.1182/hematology.2023000467
  title: 'Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease'
  findings: []
- reference: DOI:10.3389/fphys.2024.1369120
  title: 'Impact of intravascular hemolysis on functional and molecular alterations in the urinary bladder: implications for an overactive bladder in sickle cell disease'
  findings: []
- reference: DOI:10.3389/fphys.2024.1474569
  title: Therapeutics for sickle cell disease intravascular hemolysis
  findings: []
- reference: DOI:10.3390/jcm13216404
  title: The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia
  findings: []
📚

References & Deep Research

References

12
DOI:10.1001/jama.2008.598
Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
No top-level findings curated for this source.
DOI:10.1001/jama.294.1.81
Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease
No top-level findings curated for this source.
DOI:10.1007/s00277-025-06216-1
A review on disease modifying pharmacologic therapies for sickle cell disease
No top-level findings curated for this source.
DOI:10.1016/j.bvth.2024.100015
Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation
No top-level findings curated for this source.
DOI:10.1056/nejmoa2309676
Exagamglogene Autotemcel for Severe Sickle Cell Disease
No top-level findings curated for this source.
DOI:10.1080/17474086.2017.1327809
Heme-mediated cell activation: the inflammatory puzzle of sickle cell anemia
No top-level findings curated for this source.
DOI:10.1182/blood-2013-04-495887
Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease
No top-level findings curated for this source.
DOI:10.1182/blood-2013-10-529982
Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease
No top-level findings curated for this source.
DOI:10.1182/hematology.2023000467
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease
No top-level findings curated for this source.
DOI:10.3389/fphys.2024.1369120
Impact of intravascular hemolysis on functional and molecular alterations in the urinary bladder: implications for an overactive bladder in sickle cell disease
No top-level findings curated for this source.
DOI:10.3389/fphys.2024.1474569
Therapeutics for sickle cell disease intravascular hemolysis
No top-level findings curated for this source.
DOI:10.3390/jcm13216404
The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Sickle Cell Disease
  • Category: Mendelian
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 32

Key Pathophysiology Nodes

  • Hemoglobin Polymerization
  • Red Blood Cell Sickling
  • Vaso-Occlusion
  • Chronic Hemolysis
  • Chronic Organ Damage
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1001/jama.2008.598
  • DOI:10.1001/jama.294.1.81
  • DOI:10.1007/s00277-025-06216-1
  • DOI:10.1016/j.bvth.2024.100015
  • DOI:10.1056/nejmoa2309676
  • DOI:10.1080/17474086.2017.1327809
  • DOI:10.1182/blood-2013-04-495887
  • DOI:10.1182/blood-2013-10-529982
  • DOI:10.1182/hematology.2023000467
  • DOI:10.3389/fphys.2024.1369120
  • DOI:10.3389/fphys.2024.1474569
  • DOI:10.3390/jcm13216404
Falcon ▸
Pathophysiology description (current understanding)
Edison Scientific Literature 34 citations 2025-12-18T00:11:07.717394

Pathophysiology description (current understanding) SCD arises from a single missense variant in HBB (β6 Glu→Val) that promotes deoxygenated hemoglobin S (HbS) polymerization, driving red cell sickling, membrane injury, ion dysregulation, dehydration, and premature hemolysis. Intravascular hemolysis releases cell-free hemoglobin, heme, and erythrocyte arginase-1, which together mediate nitric oxide (NO) depletion, oxidative stress, endothelial activation, sterile inflammation, and a thromboinflammatory vasculopathy characterized by multicellular adhesion and vaso-occlusion. Hemolysis-derived heme triggers endothelial TLR4 signaling that rapidly releases Weibel–Palade body cargo (P-selectin and von Willebrand factor [VWF]), enhancing leukocyte rolling/adhesion and microvascular stasis. Heme and oxidized hemoglobin promote neutrophil extracellular traps (NETs), while emerging data implicate mast cell extracellular traps (MCETs) in neural and vascular injury that can exacerbate pain. These axes—HbS polymerization/sickling, hemolysis/NO depletion, adhesion/vaso-occlusion, and thromboinflammation—interact to cause acute crises (pain, acute chest) and chronic organ damage (pulmonary hypertension, renal and cerebrovascular disease). Foundational and recent studies support these mechanisms and identify therapeutic entry points, including HbF induction, heme scavenging, selectin blockade, metabolic modulation of red cells (PK activators), and gene editing that reactivates HbF. (ilboudo2022multiomicsapproachesto pages 20-24, belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2, guarda2017hememediatedcellactivation pages 1-5)

1) Core Pathophysiology - Primary mechanisms - HbS polymerization and red-cell dehydration: Deoxygenated HbS forms long polymers that stiffen RBCs and promote membrane damage, repeated sickling, reactive oxygen species, disordered cation flux, activation of Gardos (KCNN4) and K–Cl cotransport, and RBC dehydration/density—thus increasing sickling propensity and hemolysis. (ilboudo2022multiomicsapproachesto pages 20-24) - Hemolysis, NO scavenging, arginase axis: Cell-free hemoglobin “reacts with and scavenges NO,” while erythrocyte arginase depletes L‑arginine, reducing NO synthesis; lower arginine:ornithine and arginine:(ornithine+citrulline) ratios correlate with pulmonary hypertension (PH) severity and mortality in adults with SCD. (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18, morris2005dysregulatedargininemetabolism pages 5-7) - Heme–TLR4–WPB pathway and adhesion: Free heme activates endothelial TLR4, inducing oxidative signaling and Weibel–Palade body degranulation (surface P‑selectin and VWF strings) within minutes, which promotes leukocyte rolling/adhesion and vaso‑occlusion; TLR4 inhibition (TAK‑242) and hemopexin/haptoglobin mitigate heme‑induced stasis in SCD mice. (belcher2014hemetriggerstlr4 pages 6-9) - Thromboinflammation: Heme/oxidized Hb and inflammatory stimuli trigger NET formation; “hemolysis releases cell free hemoglobin… [that] scavenges NO” and “oxidized hemoglobin and free heme can trigger a sterile inflammatory reaction involving TLR4 activation, and stimulates neutrophils to release NETs,” which contribute to acute lung injury and vaso‑occlusion. (chen2014hemeinducedneutrophilextracellular pages 1-2) - Selectin-mediated multicellular adhesion: Endothelial/platelet P‑ and E‑selectins and leukocyte PSGL‑1 drive tethering/rolling and firm adhesion of RBCs, leukocytes, and platelets, amplifying microvascular occlusion and ischemia-reperfusion injury. (escopy2024targetingthepselectinpsgl1 pages 10-12, belcher2014hemetriggerstlr4 pages 6-9) - MCETs and pain: In SCD murine models, PAD4‑dependent mast cell extracellular traps directly injure vasculature and nerves and promote vaso‑occlusion and hyperalgesia; PAD4 inhibition reduces vascular stasis and pain behaviors. (mahadevia2025areviewon pages 6-8)

  • Dysregulated molecular pathways
  • NO signaling: Depletion by hemoglobin dioxygenation chemistry and substrate limitation via arginase; downstream sGC–cGMP vasodilatory signaling is impaired. (kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 7-8)
  • Innate immune sensing: Heme–TLR4–NF‑κB and oxidative pathways (PKC, NOX) activate endothelium and leukocytes; NETosis/MCETs propagate thromboinflammation. (belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8)

  • Adhesion pathways: Selectins (P/E), PSGL‑1, VWF, integrins (ICAM/VCAM interactions) facilitate vaso‑occlusion. (escopy2024targetingthepselectinpsgl1 pages 10-12, belcher2014hemetriggerstlr4 pages 6-9)

  • Affected cellular processes

  • RBC biomechanics and membrane transport (2,3‑DPG/ATP balance, Ca2+ influx, Gardos/K–Cl), endothelial activation/WPB exocytosis, leukocyte/platelet adhesion and NETosis/MCETosis, heme/iron handling and oxidative stress. (ilboudo2022multiomicsapproachesto pages 20-24, belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2, escopy2024targetingthepselectinpsgl1 pages 10-12)

2) Key Molecular Players - Genes/Proteins (HGNC symbol) - HBB (β-globin; mutant HbS) – causal. (ilboudo2022multiomicsapproachesto pages 20-24) - BCL11A (erythroid enhancer target for HbF reactivation by gene editing). (frangoul2024exagamglogeneautotemcelfor pages 4-6) - SELP (P‑selectin), SELE (E‑selectin), SELPLG (PSGL‑1) – adhesion. (escopy2024targetingthepselectinpsgl1 pages 10-12) - VWF; WPB cargo. (belcher2014hemetriggerstlr4 pages 6-9) - TLR4 – heme sensing on endothelium. (belcher2014hemetriggerstlr4 pages 6-9) - ARG1 – arginase‑1; NOS isoforms (NOS3/eNOS). (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 5-7) - NOX components, PKC; NF‑κB – signaling. (belcher2014hemetriggerstlr4 pages 6-9) - PAD4 (PADI4) – trap formation (MCET/NET). (mahadevia2025areviewon pages 6-8)

  • Chemical entities (CHEBI where applicable)

  • Hemoglobin/heme (CHEBI:16136/30413), NO (CHEBI:16480), L‑arginine (CHEBI:29016), 2,3‑diphosphoglycerate (CHEBI:16001), ATP (CHEBI:15422). (chen2014hemeinducedneutrophilextracellular pages 1-2, kato2008evolutionofnovel pages 2-4, rubio2024thecurrentrole pages 9-11)

  • Cell types (CL terms)

  • Erythrocyte (CL:0000232), endothelial cell (CL:0000115), neutrophil (CL:0000775), mast cell (CL:0000097), platelet (CL:0000233), monocyte (CL:0000576). (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9, mahadevia2025areviewon pages 6-8)

  • Anatomical locations (UBERON)

  • Microvasculature (UBERON:0001981), lung (UBERON:0002048), liver (UBERON:0002107), kidney (UBERON:0002113), spleen (UBERON:0002106), urinary bladder (UBERON:0001255). (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9, xue2024therapeuticsforsickle pages 1-2)

3) Biological Processes (candidate GO annotations; evidence-based) - HbS polymerization and red-cell dehydration: “hemoglobin polymerization” (GO:0030492), “regulation of cation transport” (GO:0051924), “potassium ion transmembrane transport” (GO:0071805), “erythrocyte homeostasis” (GO:0034101). (ilboudo2022multiomicsapproachesto pages 20-24) - Endothelial activation/WPB exocytosis: “exocytosis” (GO:0006887), “endothelial cell activation” (GO:0042118), “response to heme” (GO:1903409). (belcher2014hemetriggerstlr4 pages 6-9) - Leukocyte/platelet adhesion and rolling: “leukocyte tethering or rolling” (GO:0050901), “cell adhesion mediated by integrin” (GO:0033627), “platelet activation” (GO:0030168). (escopy2024targetingthepselectinpsgl1 pages 10-12) - Hemolysis and NO pathway: “nitric oxide metabolic process” (GO:0046209), “arginine metabolic process” (GO:0006525), “regulation of blood pressure” (GO:0008217). (kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 7-8) - NET/MCET formation: “neutrophil extracellular trap formation” (GO:0036342), “chromatin decondensation” (GO:0031490). (chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8)

4) Cellular Components - Key loci of action: erythrocyte cytosol (HbS polymer), plasma (cell‑free Hb, heme), endothelial surface (P‑selectin/VWF strings), Weibel–Palade body, extracellular space (NETs/MCETs), caveolae/raft TLR4 signaling domains. (belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2)

5) Disease Progression - Sequence of events 1) Deoxygenation → HbS polymerization → sickling, membrane injury, Ca2+ influx → Gardos/K–Cl activation → RBC dehydration/density. (ilboudo2022multiomicsapproachesto pages 20-24) 2) Vaso‑occlusion axis: Endothelial activation (heme–TLR4) and selectin/VWF upregulation → leukocyte/platelet/RBC adhesion → microvascular stasis and ischemia-reperfusion injury. (belcher2014hemetriggerstlr4 pages 6-9, escopy2024targetingthepselectinpsgl1 pages 10-12) 3) Hemolysis axis: Intravascular hemolysis releases cell‑free Hb/heme/arginase → NO scavenging + L‑arginine depletion → vasoconstriction, endothelial dysfunction, and PH risk. (kato2008evolutionofnovel pages 2-4, morris2005dysregulatedargininemetabolism pages 7-8) 4) Thromboinflammation: Heme/oxidized Hb drive NETs (and MCETs) that scaffold thrombosis and amplify occlusion and organ injury (e.g., lung). (chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8)

  • Distinct “hemolytic” vs “viscosity/vaso-occlusive” subphenotypes can dominate specific complications (e.g., PH, leg ulcers, priapism vs frequent VOC/ACS), reflecting relative contributions of hemolysis/NO depletion vs adhesion/viscosity mechanisms. (ilboudo2022multiomicsapproachesto pages 20-24, kato2008evolutionofnovel pages 2-4)

6) Phenotypic Manifestations (with mechanism links) - Acute painful vaso-occlusive crises (VOC): adhesion/selectin–PSGL‑1 axis and thromboinflammation (NETs/MCETs). (escopy2024targetingthepselectinpsgl1 pages 10-12, chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8) - Acute chest syndrome and acute lung injury: NETosis and heme–TLR4 endothelial activation. (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9) - Pulmonary hypertension: Hemolysis-associated NO scavenging and arginase-mediated L‑arginine depletion (risk of death markedly elevated with TRV ≥2.5 m/s). (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4) - Functional asplenia and infection susceptibility (encapsulated bacteria); infections trigger VOC/ACS and contribute substantially to morbidity/mortality, especially in LMICs. (ilboudo2022multiomicsapproachesto pages 20-24) - Organ-specific dysfunction from systemic NO depletion/oxidative stress (e.g., bladder overactivity with decreased p‑eNOS/p‑nNOS and increased NOX/oxidative markers in hemolysis models). (xue2024therapeuticsforsickle pages 1-2)

Evidence items and quotes (selected) - “Heme… activates endothelial TLR4 signaling leading to WPB degranulation, NF‑κB activation” and stasis; TAK‑242 reduced heme‑ or LPS‑induced stasis in SCD mice; hemopexin/haptoglobin abrogate heme effects. URL: https://doi.org/10.1182/blood-2013-04-495887 (Belcher et al., Blood, 2014). (belcher2014hemetriggerstlr4 pages 6-9) - “Hemolysis releases cell free hemoglobin (Hb)… Free hemoglobin reacts with and scavenges NO… Oxidized hemoglobin and free heme… stimulate neutrophils to release NETs.” URL: https://doi.org/10.1182/blood-2013-10-529982 (Chen et al., Blood, 2014). (chen2014hemeinducedneutrophilextracellular pages 1-2) - Low arginine bioavailability and PH/mortality: In adults with SCD, TRV ≥2.5 m/s conferred a risk ratio for death ≈7.4; lower arginine:ornithine and arginine:(ornithine+citrulline) ratios independently associated with mortality. URL: https://doi.org/10.1001/jama.294.1.81 (Morris et al., JAMA, 2005). (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18)

Recent developments and latest research (2023–2024) - HbF reactivation by CRISPR-Cas9 (exagamglogene autotemcel, exa‑cel/Casgevy). In the phase 3 SCD study, among evaluable patients, 97% were free from severe VOCs for ≥12 consecutive months, and 100% were free from VOC hospitalizations for ≥12 months; safety consistent with busulfan-conditioning autologous HSPC transplant. URL: https://doi.org/10.1056/nejmoa2309676 (NEJM, 2024). (frangoul2024exagamglogeneautotemcelfor pages 4-6) - Selectin pathway: translational and clinical evidence establishes the biological centrality of the P‑selectin/PSGL‑1 axis; however, phase 3 results have been mixed (e.g., negative primary endpoint in STAND), prompting regulatory reassessment and regional revocation in 2023. URLs: https://doi.org/10.1016/j.bvth.2024.100015; (overview) and retrospective real‑world/center experiences. (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11) - RBC metabolic modulation (pyruvate kinase activators): Class effects include increased RBC ATP and decreased 2,3‑DPG, with early trials showing hemoglobin rises and improved RBC energetics; active development continued through 2023–2024. URL: Hematology ASH Education Program 2023 review https://doi.org/10.1182/hematology.2023000467. (rubio2024thecurrentrole pages 9-11) - Thromboinflammatory targets: NET/MCET pathways and complement/VWF/ADAMTS13 balance highlighted for future interventions; preclinical and early clinical programs include rADAMTS13 and hemopexin. (chen2014hemeinducedneutrophilextracellular pages 1-2, mahadevia2025areviewon pages 6-8) - Safety/regulatory updates for legacy agents: Crizanlizumab—mixed efficacy (phase 3 STAND negative) leading to EMA revocation (2023) and caution in observational cohorts; voxelotor—postmarketing safety concerns and mortality signals prompted withdrawal/suspension decisions in 2024. (rubio2024thecurrentrole pages 9-11)

Current applications and implementations - Hydroxyurea (cornerstone DMM): Increases HbF, lowers leukocytes/platelets and endothelial adhesion markers, improves NO signaling and reduces VOCs, ACS, transfusions, and mortality with long‑term use. Practical guidance emphasizes early initiation in children and use in adults with recurrent VOCs/ACS. URL: https://doi.org/10.3390/jcm13216404 (2024). (rubio2024thecurrentrole pages 9-11) - Selectin inhibition: While mechanistically compelling, clinical utility is uncertain due to mixed trial data; centers weigh risks, cost, and alternative DMMs; retrospective series report variable VOC trajectories and serious adverse events. (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11) - Gene therapy: Exa‑cel (Casgevy) has demonstrated high VOC‑free rates and pancellular HbF after myeloablative autologous HSPC gene editing; adoption considerations include myeloablative toxicity, infrastructure, and access disparities. (frangoul2024exagamglogeneautotemcelfor pages 4-6) - PK activators: Ongoing phase 2/3 programs (mitapivat, etavopivat) exploring clinically meaningful endpoints (Hb increase, VOCs), with phase 1/2 signals of biochemical correction (↑ATP, ↓2,3‑DPG) and hemoglobin rise. (rubio2024thecurrentrole pages 9-11)

Expert opinions and analysis (authoritative sources) - Mechanism-integrated view: Heme acts as a master DAMP; endothelial TLR4 activation is a proximal switch for WPB release and adhesion, providing rationale for heme scavenging or TLR4 pathway interventions. (belcher2014hemetriggerstlr4 pages 6-9) - NO pathway as a determinant of the “hemolytic phenotype”: Clinical associations of arginine dysregulation with PH and mortality argue for biomarker‑guided strategies and substrate/enzyme‑targeted adjuvant therapy in selected patients. (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4) - Thromboinflammation: Targeting NETs/MCETs and platelet–neutrophil/adhesion modules may complement HbF‑based and metabolic strategies; preclinical proof supports combined anti‑adhesive and anti‑DAMP therapies. (chen2014hemeinducedneutrophilextracellular pages 1-2, escopy2024targetingthepselectinpsgl1 pages 10-12, mahadevia2025areviewon pages 6-8)

Relevant statistics and data (recent and landmark) - Exa‑cel phase 3 (SCD): 97% (29/30) free from severe VOCs ≥12 months; 100% (30/30) free from VOC hospitalizations ≥12 months; median follow‑up 19.3 months. URL: https://doi.org/10.1056/nejmoa2309676 (NEJM, 2024). (frangoul2024exagamglogeneautotemcelfor pages 4-6) - Hemolysis–PH–mortality: TRV ≥2.5 m/s carried ~7.4× risk of death; low arginine:ornithine and low global arginine bioavailability independently associated with mortality (risk ratios roughly 2–3.6 depending on metric). URL: https://doi.org/10.1001/jama.294.1.81 (JAMA, 2005). (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18) - Heme–TLR4–WPB: In murine SCD models, heme rapidly induced WPB degranulation and vaso‑occlusion; TAK‑242 reduced stasis (e.g., vehicle+heme 26.4% vs TAK‑242 9.3%). URL: https://doi.org/10.1182/blood-2013-04-495887 (Blood, 2014). (belcher2014hemetriggerstlr4 pages 6-9) - NETs in SCD: Heme‑driven NETosis implicated in acute lung injury and VOC in SCD models; DNase and ROS‑modulating strategies proposed. URL: https://doi.org/10.1182/blood-2013-10-529982 (Blood, 2014). (chen2014hemeinducedneutrophilextracellular pages 1-2) - Bladder dysfunction and NO signaling (model): Intravascular hemolysis increased urinary frequency and DSM hypercontractility with decreased p‑eNOS (Ser1177), p‑nNOS (Ser1417), and p‑VASP (Ser239), and increased NOX‑2, 3‑NT, and 4‑HNE in bladder. URL: https://doi.org/10.3389/fphys.2024.1369120 (Frontiers in Physiology, 2024). (xue2024therapeuticsforsickle pages 1-2)

Structured evidence summary | Mechanistic axis | Key molecules / cells | Mechanism (concise) | 2023–2024 highlights | Representative sources (journal, year) | |---|---|---:|---|---| | HbS polymerization & RBC dehydration | HbS, HbF, Gardos (KCNN4), K-Cl cotransport | Deoxygenated HbS polymerizes → filamentous polymers → RBC sickling, membrane damage, Ca2+ dysregulation → Gardos/K-Cl mediated K+ efflux → RBC dehydration and dense, rigid cells | Continued emphasis on HbF reactivation as protective; PK activators and metabolic approaches aim to alter 2,3‑DPG/ATP to reduce sickling (clinical programs active 2023–24) | (ilboudo2022multiomicsapproachesto pages 20-24, rubio2024thecurrentrole pages 9-11) | | Adhesion / selectins & WPB release | P‑selectin, E‑selectin, PSGL‑1, Weibel–Palade bodies (VWF, P‑selectin), platelets, endothelium | Endothelial/platelet selectin expression mediates RBC/leukocyte/platelet tethering and rolling → firm adhesion → microvascular occlusion | Therapeutics targeting P‑selectin/PSGL‑1 (crizanlizumab, inclacumab, pan‑selectin agents) show mechanistic benefit; clinical outcomes mixed leading to regulatory reassessments (2023–24) | (escopy2024targetingthepselectinpsgl1 pages 10-12, belcher2014hemetriggerstlr4 pages 6-9) | | Hemolysis → NO scavenging & arginase | Cell‑free hemoglobin, heme, arginase‑1, L‑arginine, NOS | Intravascular hemolysis releases cell‑free Hb that stoichiometrically scavenges NO; concomitant arginase release depletes L‑arginine, lowering NO production → vasoconstriction, endothelial dysfunction, PH | Strong clinical associations: low arginine:ornithine and low arginine:(ornithine+citrulline) ratios correlate with pulmonary hypertension and increased mortality in cohorts (2005 foundational data reinforced in reviews) | (morris2005dysregulatedargininemetabolism pages 8-9, kato2008evolutionofnovel pages 2-4) | | Heme → TLR4 signaling (endothelium) | Free heme, TLR4, NADPH oxidase (NOX), PKC, NF‑κB, WPB (P‑selectin, VWF) | Free heme activates endothelial TLR4 → oxidative signaling → Weibel–Palade body degranulation (P‑selectin, VWF) → rapid leukocyte/platelet recruitment and vaso‑occlusion | Murine SCD models: TLR4 blockade (TAK‑242) reduced heme‑induced stasis; hemopexin/haptoglobin mitigate heme effects — supports heme scavenging strategies | (belcher2014hemetriggerstlr4 pages 6-9, guarda2017hememediatedcellactivation pages 1-5) | | NETs & platelet–neutrophil aggregates | Neutrophils, NETs (citrullinated histones, DNA), platelets, HMGB1 | Heme/oxidized Hb and inflammatory signals trigger NETosis → extracellular chromatin scaffolds bind platelets and promote thrombosis and vaso‑occlusion; platelet–neutrophil crosstalk amplifies thromboinflammation | NET inhibition (DNase, ROS scavengers) and targeting platelet–neutrophil interactions are highlighted as potential interventions in recent reviews | (chen2014hemeinducedneutrophilextracellular pages 1-2, escopy2024targetingthepselectinpsgl1 pages 10-12) | | Mast cell extracellular traps (MCETs) | Mast cells, PAD4, citrullinated histones, nerve/vascular interfaces | Sickle microenvironment (heme/inflammation) induces MCET release → direct vascular and neural injury contributing to acute/chronic pain and vaso‑occlusion in models | Emerging 2024 data implicate PAD4‑dependent MCETs in vaso‑occlusion and pain; PAD4 inhibition ameliorated stasis and hyperalgesia in mice | (guarda2017hememediatedcellactivation pages 1-5, mahadevia2025areviewon pages 6-8) | | Complement / VWF axis & ADAMTS13 | Complement proteins, VWF, ADAMTS13, endothelium | Hemolysis/inflammation dysregulate VWF release and complement activation → microthrombotic injury; restoring ADAMTS13 or modulating complement may reduce organ injury | Preclinical and early clinical work (rADAMTS13, complement inhibitors, hemopexin) cited as promising approaches in 2023–24 reviews | (belcher2014hemetriggerstlr4 pages 6-9, mahadevia2025areviewon pages 6-8) | | PK activators (red‑cell metabolism) | Pyruvate kinase (PKR), 2,3‑DPG, ATP (RBC) | PK activators increase RBC ATP and lower 2,3‑DPG → higher O2 affinity, reduced HbS polymerization tendency, improved RBC deformability and hydration | 2023–24: multiple PK activators (mitapivat, etavopivat, AG‑946) progressed in trials; phase‑1/2 signals show ↑Hb and biochemical shifts (↓2,3‑DPG, ↑ATP) | (rubio2024thecurrentrole pages 9-11, escopy2024targetingthepselectinpsgl1 pages 10-12) | | Gene therapy (exa‑cel) approvals & outcomes | BCL11A editing, CD34+ HSPCs, CRISPR‑Cas9 | Ex vivo CRISPR editing of BCL11A erythroid enhancer → reactivation of γ‑globin (HbF) in erythroid lineage → reduced sickling and VOCs | Exa‑cel (Casgevy) demonstrated high rates of freedom from severe VOCs and durable HbF induction in phase‑3 data; regulatory approvals occurred in 2023 (UK, USA) with published NEJM outcomes (2024) | (frangoul2024exagamglogeneautotemcelfor pages 4-6) | | Selectin inhibition — mixed evidence | Crizanlizumab, inclacumab, rivipansel, sevuparin | Blocking P‑selectin/PSGL‑1 reduces multicellular adhesion and theoretically prevents VOCs; clinical benefit depends on trial/context and endpoints | Crizanlizumab showed VOC reduction in earlier trials but Phase‑3 STAND failed to meet primary endpoint leading to regulatory reassessments (2023–24); other selectin agents show variable results | (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11) | | Voxelotor (Hb‑oxygen affinity modifier) withdrawal signals | Voxelotor (Oxbryta), hemoglobin stabilization | Increases Hb by stabilizing oxygenated HbS (↓polymerization) improving anemia metrics | Approved earlier (2019/2022 regulatory actions), but 2024–2025 safety signal reports and registry/FAERS analyses prompted market withdrawal/reevaluation due to mortality and safety concerns in post‑approval data | (rubio2024thecurrentrole pages 9-11) | | Infection / functional asplenia & global burden | Splenic dysfunction, encapsulated bacteria, adaptive/innate immune defects | Functional asplenia + immune defects → high risk for invasive infection; infections also trigger VOCs and acute chest syndrome | Reviews (2023–24) emphasize infection as major morbidity/mortality driver in LMICs and the persistent care gap for prophylaxis/vaccination | (ilboudo2022multiomicsapproachesto pages 20-24, rubio2024thecurrentrole pages 9-11) | | Bladder / organ NO signaling with hemolysis | eNOS, nNOS, VASP, NOX enzymes, oxidative markers | Hemolysis reduces NO signaling (cell‑free Hb + arginase), increases oxidative stress → organ‑specific endothelial / smooth muscle dysfunction (e.g., bladder overactivity) | 2024 experimental work links intravascular hemolysis to reduced phosphorylated eNOS/nNOS and increased NOX/oxidative markers in bladder models, supporting systemic NO‑depletion effects on organs | (morris2005dysregulatedargininemetabolism pages 8-9, xue2024therapeuticsforsickle pages 1-2) |

Table: Concise table linking core sickle cell disease mechanistic axes to key molecules, short mechanisms, 2023–2024 developments, and representative source citations (context IDs) useful for knowledge‑base curation and evidence mapping.

Gene/protein annotations (HGNC) with ontology terms (examples) - HBB (HGNC:4827): hemoglobin complex (GO:0005833); hemoglobin polymerization (GO:0030492). Evidence: HbS polymerization drives sickling. (ilboudo2022multiomicsapproachesto pages 20-24) - BCL11A (HGNC:13222): regulation of hemoglobin F expression; target of exa‑cel gene editing to reactivate γ‑globin. (frangoul2024exagamglogeneautotemcelfor pages 4-6) - TLR4 (HGNC:11848): toll-like receptor signaling pathway (GO:0002224); response to heme (GO:1903409). (belcher2014hemetriggerstlr4 pages 6-9) - SELP/SELE/SELPLG (HGNC:10720/10719/10753): leukocyte tethering or rolling (GO:0050901), cell adhesion (GO:0007155). (escopy2024targetingthepselectinpsgl1 pages 10-12) - ARG1 (HGNC:663): arginine metabolic process (GO:0006525); negative regulation of nitric oxide biosynthetic process (GO:0046209 context). (morris2005dysregulatedargininemetabolism pages 7-8) - VWF (HGNC:12726): blood coagulation (GO:0007596); Weibel–Palade body (GO:0042582). (belcher2014hemetriggerstlr4 pages 6-9) - PADI4 (HGNC:18350): protein citrullination; neutrophil extracellular trap formation (GO:0036342). (mahadevia2025areviewon pages 6-8)

Phenotype associations (HP terms; examples) - HP:0002092 Acute chest syndrome (NET/adhesion/heme–TLR4). (chen2014hemeinducedneutrophilextracellular pages 1-2, belcher2014hemetriggerstlr4 pages 6-9) - HP:0001945 Hemolytic anemia (HbS polymerization/hemolysis). (ilboudo2022multiomicsapproachesto pages 20-24) - HP:0002905 Pulmonary hypertension (NO scavenging/arginase). (morris2005dysregulatedargininemetabolism pages 7-8, kato2008evolutionofnovel pages 2-4) - HP:0002093 Recurrent infections/functional asplenia (immune dysfunction). (ilboudo2022multiomicsapproachesto pages 20-24) - HP:0001873 Pain crisis (adhesion/thromboinflammation/MCETs). (escopy2024targetingthepselectinpsgl1 pages 10-12, mahadevia2025areviewon pages 6-8)

Cell type involvement (CL terms; examples) - Erythrocytes (CL:0000232) – HbS polymerization/ion transport/hemolysis. (ilboudo2022multiomicsapproachesto pages 20-24) - Endothelial cells (CL:0000115) – TLR4 activation/WPB release. (belcher2014hemetriggerstlr4 pages 6-9) - Neutrophils (CL:0000775) – NETosis and adhesion. (chen2014hemeinducedneutrophilextracellular pages 1-2) - Mast cells (CL:0000097) – MCETs in neural/vascular injury and pain. (mahadevia2025areviewon pages 6-8) - Platelets (CL:0000233) – adhesion/aggregate with NETs. (escopy2024targetingthepselectinpsgl1 pages 10-12)

Anatomical locations (UBERON; examples) - Microvasculature (UBERON:0001981), lung (UBERON:0002048), kidney (UBERON:0002113), spleen (UBERON:0002106), bladder (UBERON:0001255). (belcher2014hemetriggerstlr4 pages 6-9, chen2014hemeinducedneutrophilextracellular pages 1-2, xue2024therapeuticsforsickle pages 1-2)

Chemical entities (CHEBI; examples) - Heme (CHEBI:30413), nitric oxide (CHEBI:16480), L‑arginine (CHEBI:29016), ATP (CHEBI:15422), 2,3‑DPG (CHEBI:16001). (chen2014hemeinducedneutrophilextracellular pages 1-2, kato2008evolutionofnovel pages 2-4, rubio2024thecurrentrole pages 9-11)

Citations (URLs and publication dates) - Belcher et al., Blood, 2014 (Jan). Heme–TLR4–WPB/adhesion link in SCD. URL: https://doi.org/10.1182/blood-2013-04-495887 (belcher2014hemetriggerstlr4 pages 6-9) - Chen et al., Blood, 2014 (Jun). Hemolysis → NO scavenging; heme → NETs/acute lung injury. URL: https://doi.org/10.1182/blood-2013-10-529982 (chen2014hemeinducedneutrophilextracellular pages 1-2) - Morris et al., JAMA, 2005 (Jul). Arginase/NO pathway, PH and mortality risk. URL: https://doi.org/10.1001/jama.294.1.81 (morris2005dysregulatedargininemetabolism pages 7-8, morris2005dysregulatedargininemetabolism pages 1-2, morris2005dysregulatedargininemetabolism pages 12-18) - Frangoul et al., NEJM, 2024 (May). Exa‑cel phase 3 outcomes. URL: https://doi.org/10.1056/nejmoa2309676 (frangoul2024exagamglogeneautotemcelfor pages 4-6) - Escopy & Chaikof, Blood Vessels, Thrombosis & Hemostasis, 2024 (Sep). Selectin pathway therapeutics overview. URL: https://doi.org/10.1016/j.bvth.2024.100015 (escopy2024targetingthepselectinpsgl1 pages 10-12) - Rubio & Marina, J Clin Med, 2024 (Oct). Hydroxyurea role; regulatory context for crizanlizumab/voxelotor; PK activators overview. URL: https://doi.org/10.3390/jcm13216404 (rubio2024thecurrentrole pages 9-11) - Silveira et al., Front Physiol, 2024 (Jul). Hemolysis → bladder NO signaling and oxidative stress. URL: https://doi.org/10.3389/fphys.2024.1369120 (xue2024therapeuticsforsickle pages 1-2)

Notes on evidence strength and gaps - Landmark mechanistic data (Belcher; Chen) and clinical associations (Morris; Kato/Gladwin) remain foundational. 2023–2024 contributions strengthen translational axes (selectin therapeutics) and show transformative efficacy with exa‑cel for severe SCD. Mixed outcomes and evolving safety signals for selectin inhibitors and Hb‑oxygen affinity modifiers highlight the need for robust, event‑driven endpoints and long‑term pharmacovigilance. (escopy2024targetingthepselectinpsgl1 pages 10-12, rubio2024thecurrentrole pages 9-11, frangoul2024exagamglogeneautotemcelfor pages 4-6)

References

  1. (ilboudo2022multiomicsapproachesto pages 20-24): Y Ilboudo. Multi-omics approaches to sickle cell disease heterogeneity. Unknown journal, 2022.

  2. (belcher2014hemetriggerstlr4 pages 6-9): John D. Belcher, Chunsheng Chen, Julia Nguyen, Liming Milbauer, Fuad Abdulla, Abdu I. Alayash, Ann Smith, Karl A. Nath, Robert P. Hebbel, and Gregory M. Vercellotti. Heme triggers tlr4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 123 3:377-90, Jan 2014. URL: https://doi.org/10.1182/blood-2013-04-495887, doi:10.1182/blood-2013-04-495887. This article has 788 citations and is from a highest quality peer-reviewed journal.

  3. (chen2014hemeinducedneutrophilextracellular pages 1-2): Grace Chen, Dachuan Zhang, Tobias A. Fuchs, Deepa Manwani, Denisa D. Wagner, and Paul S. Frenette. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood, 123 24:3818-27, Jun 2014. URL: https://doi.org/10.1182/blood-2013-10-529982, doi:10.1182/blood-2013-10-529982. This article has 421 citations and is from a highest quality peer-reviewed journal.

  4. (guarda2017hememediatedcellactivation pages 1-5): Caroline Conceição da Guarda, Rayra Pereira Santiago, Luciana Magalhães Fiuza, Milena Magalhães Aleluia, Júnia Raquel Dutra Ferreira, Camylla Vilas Boas Figueiredo, Setondji Cocou Modeste Alexandre Yahouedehou, Rodrigo Mota de Oliveira, Isa Menezes Lyra, and Marilda de Souza Gonçalves. Heme-mediated cell activation: the inflammatory puzzle of sickle cell anemia. Expert Review of Hematology, 10:533-541, May 2017. URL: https://doi.org/10.1080/17474086.2017.1327809, doi:10.1080/17474086.2017.1327809. This article has 39 citations and is from a peer-reviewed journal.

  5. (morris2005dysregulatedargininemetabolism pages 7-8): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.

  6. (kato2008evolutionofnovel pages 2-4): GJ Kato and MT Gladwin. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA, 300 22:2638-46, Dec 2008. URL: https://doi.org/10.1001/jama.2008.598, doi:10.1001/jama.2008.598. This article has 85 citations.

  7. (morris2005dysregulatedargininemetabolism pages 1-2): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.

  8. (morris2005dysregulatedargininemetabolism pages 12-18): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.

  9. (morris2005dysregulatedargininemetabolism pages 5-7): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.

  10. (escopy2024targetingthepselectinpsgl1 pages 10-12): Samira Escopy and Elliot L. Chaikof. Targeting the p-selectin/psgl-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels, Thrombosis & Hemostasis, 1:100015, Sep 2024. URL: https://doi.org/10.1016/j.bvth.2024.100015, doi:10.1016/j.bvth.2024.100015. This article has 21 citations.

  11. (mahadevia2025areviewon pages 6-8): Himil Mahadevia, Ben Ponvilawan, Ujjwal Madan, Parth Sharma, Hana Qasim, and Anuj Shrestha. A review on disease modifying pharmacologic therapies for sickle cell disease. Annals of Hematology, 104:881-893, Jan 2025. URL: https://doi.org/10.1007/s00277-025-06216-1, doi:10.1007/s00277-025-06216-1. This article has 8 citations and is from a peer-reviewed journal.

  12. (frangoul2024exagamglogeneautotemcelfor pages 4-6): Haydar Frangoul, Franco Locatelli, Akshay Sharma, Monica Bhatia, Markus Mapara, Lyndsay Molinari, Donna Wall, Robert I. Liem, Paul Telfer, Ami J. Shah, Marina Cavazzana, Selim Corbacioglu, Damiano Rondelli, Roland Meisel, Laurence Dedeken, Stephan Lobitz, Mariane de Montalembert, Martin H. Steinberg, Mark C. Walters, Michael J. Eckrich, Suzan Imren, Laura Bower, Christopher Simard, Weiyu Zhou, Fengjuan Xuan, Phuong Khanh Morrow, William E. Hobbs, and Stephan A. Grupp. Exagamglogene autotemcel for severe sickle cell disease. New England Journal of Medicine, 390:1649-1662, May 2024. URL: https://doi.org/10.1056/nejmoa2309676, doi:10.1056/nejmoa2309676. This article has 314 citations and is from a highest quality peer-reviewed journal.

  13. (rubio2024thecurrentrole pages 9-11): Montserrat López Rubio and María Argüello Marina. The current role of hydroxyurea in the treatment of sickle cell anemia. Journal of Clinical Medicine, 13:6404, Oct 2024. URL: https://doi.org/10.3390/jcm13216404, doi:10.3390/jcm13216404. This article has 24 citations and is from a poor quality or predatory journal.

  14. (xue2024therapeuticsforsickle pages 1-2): Jianyao Xue and Xiang-An Li. Therapeutics for sickle cell disease intravascular hemolysis. Frontiers in Physiology, Sep 2024. URL: https://doi.org/10.3389/fphys.2024.1474569, doi:10.3389/fphys.2024.1474569. This article has 1 citations and is from a poor quality or predatory journal.

  15. (morris2005dysregulatedargininemetabolism pages 8-9): C. Morris, G. Kato, M. Poljakovic, Xunde Wang, W. Blackwelder, V. Sachdev, S. Hazen, E. Vichinsky, S. Morris, and M. Gladwin. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 294 1:81-90, Jul 2005. URL: https://doi.org/10.1001/jama.294.1.81, doi:10.1001/jama.294.1.81. This article has 905 citations.